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Abstract 
The transcriptional programs governing the decision of mammary epithelial stem 
and progenitor cells to self-renew or differentiate are still not completely outlined. 
Previous evidences pointed out the role of Myc, and in particular of its repressive 
activity with Miz1, in these processes. Since the presence of stem-like cells within 
the tumor, the so-called cancer stem cells (CSCs), is now considered crucial for 
tumor initiation and maintenance, clarifying this aspect of Myc biology could be 
relevant in understanding its contribution to the genesis of breast cancer. Here, we 
used RNA-seq technology to profile the transcriptional programs regulated by Myc 
in two different settings. First, we studied immortalized mammary epithelial cells, in 
which we induced either Myc loss or gain of function. In this setting, Myc 
contributed to the positive and negative regulation of different sets of genes. 
Activated genes are involved in proliferation, metabolism, ribosomal biogenesis, 
mitochondrial organization, chromatin modification, RNA processing and 
modification. Repressed genes, on the other hand, were mainly involved in 
lysosome and vesicle-mediated transport, angiogenesis, cell death, extracellular 
matrix interaction, cell adhesion regulation, epithelial development and 
morphogenesis. Second, we studied the effect of Myc activation in mammosphere 
cultures, which provide a measure of stem cell activity. We demonstrate that Myc, 
when overexpressed, is able to promote self-renewal of mammary epithelial stem 
cells, as assessed by increased mammosphere expansion, and confirmed by 
mammary gland reconstitution assays in vivo. This activity of Myc is in part 
dependent on the interaction with the co-repressor protein Miz1, since the Myc 
mutant V394D (hereby Myc VD), impaired in Miz1 binding, is defective in 
promoting self-renewal. Overexpression of Myc in mammospheres was associated 
with the de-regulated expression of about three thousand genes, with similar 
numbers of up- and down-regulated genes. A group of around nine hundred genes 
 15 
was specifically repressed by Myc WT and not by the VD mutant. Surprisingly, the 
overlap between the groups of regulated genes in those mammary epithelial cells 
in adhesion or grown as mammospheres was limited, illustrating the context-
dependency of Myc-dependent responses. Thus, transcriptional repression via 
Miz1 may constitute one of the mechanisms through which Myc sustains 
mammary epithelial cell self-renewal. We are currently setting a functional screen, 
among genes repressed in a Miz1-dependent manner, to identify those that are 
critical in this process. Our study shall shed light on the mechanisms through 
which Myc regulates self-renewal in mammary epithelial stem and progenitor cells. 
Understanding this could be crucial in order to clarify the physiopathological roles 
of Myc in the mammary gland. 
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1. Introduction 
 
1.1 Myc: discovery and structure  
The proto-oncogene c-MYC was discovered over three decades ago as 
homologous of the myelocytomatosis viral oncogene (v-Myc) and belongs to a 
family comprising also N-MYC (Shwab, Alitalo, & Klemphauer, 1983) and L-MYC 
(Nau et al., 1985). In normal conditions c-MYC expression is finely regulated in 
response to stimuli coming from the extracellular surrounding and mainly reflects 
the cellular growth state: it is induced by mitogenic stimuli and repressed by cell 
contact and differentiation stimuli (Oster, Ho, Soucie, & Penn, 2002). In turn, MYC, 
dimerizing with its partner protein MAX, regulates many biological activities 
(proliferation, cell growth, apoptosis, stemness/differentiation, genomic stability, 
adhesion/migration, angiogenesis etc.) either activating or repressing the 
transcription of specific sets of genes (Amati, Littlewood, Evan, & Land, 1993; 
Blackwell, Kretzner, Blackwood, Eisenman, & Weintraub, 1990; Blackwood & 
Eisenman, 1991; Herkert & Eilers, 2010; Kress, Sabò, & Amati, 2015). 
In mouse, homozygous deletion of c-myc is embryonic lethal before 10.5 days of 
gestation (Davis, Wims, Spotts, Hann, & Bradley, 1993) and conditional depletion 
of c-myc demonstrated its crucial function in proliferation and cell growth (de 
Alboran et al., 2001; Perna et al., 2012; Trumpp et al., 2001). On the other side, 
ectopic c-myc over-expression confirmed its association with hyperproliferation 
and tumor development (Dang, 2012). As a matter of fact, MYC is often 
deregulated in human cancers by mutations, chromosomal translocation or 
amplification (Meyer & Penn, 2008), as well as by de-regulation of upstream 
signaling pathways (e.g. Ras, Wnt, Notch) (He et al., 1998; Sears, Leone, 
DeGregori, & Nevins, 1999; Sharma et al., 2006). Altogether, Myc over-expression 
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is a common feature of cancer. The MYC protein is a 439-residue transcription 
factor of the basic helix-loop-helix leucine zipper (bHLH-LZ) family. The N-
terminus of Myc protein is composed by two homology boxes (box I, aa 44-63, and 
box II, aa 128-143, regions highly conserved among the Myc family members) and 
includes its Transactivation Domain (TAD, aa 1-143) (Figure 1A). This domain of 
Myc is essential for transformation and transcriptional activation/repression, 
ensuring the interaction with a plethora of transcription factors and co-activators 
(Kato, Barrett, Villa-Garcia, & Dang, 1990; Meyer & Penn, 2008; Oster et al., 
2002). Moreover, the N-terminus contains two tightly controlled phosphorylation 
sites (Thr58 and Ser62) that regulate Myc stability and degradation (Sears et al., 
2000). The Myc homology boxes IIIa (aa 180-199, conserved in c- and N- Myc), 
IIIb (aa 259-270) and IV (aa 304-324) are located in the middle of Myc protein, 
together with the Nuclear Localization Signal (NLS, aa 320-328 aa) (Figure 1A). 
The C-terminus of Myc includes its bHLH-LZ domain, composed of the helix-loop-
helix-leucine zipper domain (HLH-LZ, aa 370-439), responsible dimerization with 
Max, immediately preceded by the Basic Region (BR, aa 355-369), essential for 
DNA binding (Blackwell et al., 1990) (Figure 1A). Myc/Max dimers preferentially 
associate with the DNA motif CACGTG (E-box) and variants thereof (Blackwood & 
Eisenman, 1991). As for other HLH and bHLH-LZ proteins, dimerization can occur 
in solution and is a pre-requisite for DNA binding. The crystal structure of DNA-
bound bHLH-LZ domains provided a direct visualization of this phenomenon (S. K. 
Nair & Burley, 2003), bHLH dimers positioning the BR of both proteins for insertion 
into the major groove of the DNA double helix (Figure 1B). 
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Figure 1: Myc/Max structure and interaction. (A) Schematic representation of human MYC and MAX 
proteins. MYC contains four homology boxes (I-IV, including a Nuclear Localization Signal (NLS)), a 
Transactivation Domain (TAD), a Basic Region (BR, for the binding to the chromatin) and an Helix-Loop-Helix-
Leucine Zipper domain (bHLH-LZ, for the interaction with MAX) (modified from Meyer & Penn, 2008). (B) X-
ray structure of Myc (red) and Max (blue) heterodimer interacting with the double helix of the DNA (modified 
by Wikipedia from S. K. Nair & Burley, 2003)  
 
1.2 Myc: role in transcriptional activation 
As previously mentioned, Myc is a bHLH-LZ transcription factor that, by 
heterodimerizing with Max, can activate or repress gene transcription. Myc/Max 
dimers bind preferentially the E-boxes, very common sequences in the genome 
acting as transcription factors binding sites (Desbarats, Gaubatz, & Eilers, 1996). 
The general motif, bound by bHLH and bHLH-LZ proteins, is CANNTG (where N 
can be any nucleotide); in particular the palindromic canonical sequence bound by 
Myc and Max is CACGTG (Eilers & Eisenman, 2008; Oster et al., 2002). This 
interaction ensures Myc functions such as cell cycle progression, apoptosis and 
cellular transformation (Amati et al., 1993; Blackwell et al., 1990; Blackwood & 
Eisenman, 1991). 
Max or ‘Myc-associated factor X’ is a bHLH-LZ transcription factor able to 
heterodimerize with Myc to allow its transcriptional activity (Amati et al., 1993; 
1992). In addiction, Max is able to homodimerize or heterodimerize with other 
proteins belonging to the same class of transcription factors, such as Mad or Mxl1, 
that therefore act as Myc antagonists (Grandori, Cowley, James, L. P., & 
Eisenman, 2000). 
Copyright © 2015 Nature Publishing Group Copyright © 2003 Cell Press 
B A 
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In vivo, the E-box may not be the sole, or even the principal, determinant of DNA 
binding by Myc (Jiannan Guo et al., 2014; Sabò & Amati, 2014). Chromatin 
binding analyses have shown a preferential association of Myc to CpG islands, 
active chromatin features (H3K4me3, H3K27ac), presence of the basal 
transcription machinery and sites hypersensitive to digestion by DNaseI (Deaton & 
Bird, 2011; Fernandez, 2003; Guccione et al., 2006; C. Y. Lin et al., 2012; 
Martinato, Cesaroni, Amati, & Guccione, 2008; Nie et al., 2012; Sabò et al., 2014; 
Zeller et al., 2006). In particular, genome-wide binding profiles have pointed out 
that Myc occupies both active promoters and distal sites (enhancers), depending 
on its expression levels. In particular, at physiological level (low expression), Myc 
preferentially binds high affinity sites, containing E-box sequences; while at supra-
physiological level (high expression), it can “invade” also other low affinity sites 
such as promoter and enhancers in an active chromatin state (C. Y. Lin et al., 
2012; Nie et al., 2012; Sabò et al., 2014; Walz et al., 2014).  
Starting from the widespread genomic distribution of Myc, two recent studies have 
questioned the presence of a Myc-specific transcriptional program, proposing 
instead that Myc acts as ‘amplifier’ of those programs already active in the cell. 
According to this model, Myc interacts with all active loci, invading also active 
enhancers, and that leads to an increase recruitment of the P-TEFb complex to 
promoters and consequently of the RNA polymerase processivity. Therefore, Myc 
would act always as a transcriptional activator, and that would be the cause of the 
increment in the RNA content per cell (the so-called “RNA amplification”) (C. Y. Lin 
et al., 2012; Nie et al., 2012). 
The alternative scenario proposes that Myc is as transcriptional activator/repressor 
of distinct gene sets, arguing that the RNA amplification, when present, occurs 
only as a secondary consequence of the activity of Myc-specific targets (Sabò et 
al., 2014). Indeed, among Myc-regulated genes, the main enriched ontology 
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categories are related to protein synthesis, cell proliferation/growth, energetic 
metabolism, RNA processing etc. Thus, global increase in RNA levels is 
associated to DNA synthesis and increment in cell size, and occurs only 
concurrently with Myc selective transcriptional regulation (Kress et al., 2015). This 
model reconciles the phenomenon of RNA amplification with the Myc-dependent 
biological activities individuated so far. In this regard, the main transcriptional 
activations of Myc are listed below (Figure 2): 
• Cell cycle/proliferation: Myc is an early growth response gene; in response to 
mitogens, it induces cell cycle transition from G0 to S phase or progression in 
G1 (Amati, Alevizopoulos, & Vlach, 1998; Oster et al., 2002). 
• Protein synthesis/Ribosome biogenesis: Myc induces the synthesis of 
ribosomal RNA (rRNA), ribosomal proteins and transfer RNA (tRNA) promoting 
the activity of the RNA Polymerase I, II and III respectively (Arabi et al., 2005; 
Gomez-Roman, Grandori, Eisenman, & White, 2003; Ji et al., 2011). 
• Metabolism: Myc regulates several enzymes involved in glucose metabolism 
(e.g. enolase A, hexokinase, lactate dehydrogenase, phosphor-fructokinase, 
glucose transporter) or lipogenesis (e.g. carnitine-palmitoyl transferase 1A) 
enhancing glucose uptake, glycolysis and fat acid oxidation; it has also a pivotal 
role in mitochondrial biogenesis and function, iron metabolism, purine and 
pyrimidine biosynthetic pathways (Dang et al., 2006; Stine, Walton, Altman, 
Hsieh, & Dang, 2015). 
• Cell growth: Myc roles both in cell metabolism and in protein synthesis 
regulation cause accumulation of cell mass/size, thus promoting cell growth 
(Iritani & Eisenman, 1999; Schuhmacher et al., 1999). 
• RNA processing/stabilization: Myc induces expression of alternative splicing 
factors (e.g. serine/arginine-rich splicing factor 1, protein-tyrosine phosphatase-
β) (Hirsch et al., 2015; Koh et al., 2015) or regulates the activity of other RNA 
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binding proteins able to influence transcripts stability or quality control (e.g. 
tristetraprolin, Smad nuclear-interacting protein 1) (Cleveland et al., 2012; Fujii 
et al., 2006). 
• Apoptosis: Myc up-regulates key pro-apoptotic molecules such as Bax, Bak, 
BH3-only family (e.g Bim, Noxa) (Meyer & Penn, 2008; Oster et al., 2002). 
 
Figure 2: Myc transcriptional activation functions. The main pathways, and their components, that are 
regulated by Myc/Max transcriptional activation. This transcriptional network results in a global RNA 
production. The genes listed are examples (from Kress et al., 2015). 
 
1.3 Myc: role in transcriptional repression 
Beyond its function as an activator, Myc also acts as transcriptional repressor, in 
particular when over-expressed (Walz et al., 2014). First, Myc is able to down-
regulate its own expression; this repression is proportional to Myc cellular 
concentration thus it acts as a negative feedback mechanism for maintaining cell 
homeostasis (L. J. Penn, Brooks, Laufer, & Land, 1990). Gene repression by Myc 
has been proposed to occur through interaction with several other transcription 
factors among which Miz1 (Staller et al., 2001), Sp1/Sp3 (Gartel et al., 2001), NF-
Y (Izumi et al., 2001), Smad2/Smad3 (Feng, Liang, Liang, Zhai, & Lin, 2002) and 
YY1 (Shrivastava et al., 1993), the best characterized and possibly the most 
general partner in Myc-mediated repression being Miz1 (Peukert et al., 1997), 
Copyright © 2015 Nature Publishing Group 
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which will be introduced in further detail below. The main functional categories of 
genes repressed by Myc are briefly listed here: 
• Negative regulators of cell cycle/proliferation: c-Myc represses the 
expression of anti-mitogenic molecules such as Gadd45, Gadd153, c/EBPα, 
Cyclin-Dependent Kinase Inhibitors (CDKIs) as p15INK4B (Cdkn2b), p18INK4C 
(Cdkn2c), p21CIP1 (Cdkn1a), p27 KIP1 (Cdkn1b), p57KIP2 (Cdkn1c) (Amati et al., 
1998; Gartel et al., 2001; Steffi Herold et al., 2002; Knoepfler, Cheng, & 
Eisenman, 2002; Oster et al., 2002; Seoane, Le, & Massagué, 2002; Staller et 
al., 2001; Warner, Blain, Seoane, & Massagué, 1999). In this context, it is worth 
mentioning the antagonistic role between Myc and TGFβ signaling: in epithelial 
cells TGFβ is a major anti-mitogenic signal. Through its effectors, the Smad 
proteins, it is able to induce cell cycle arrest in G1 phase, by up-regulating the 
Cdk4-inhibitor p15INK4B and down-regulating c-myc expression. Forced 
expression of Myc prevents TGFβ-dependent cytostatic response, since it 
induces Cyclin D expression and blocks the Smad-dependent transcription of 
p15INK4B (Seoane et al., 2001; Warner et al., 1999). 
• Survival: Myc down-regulates anti-apoptotic proteins such as Bcl-2 and Bcl-XL 
(Patel & McMahon, 2006). Moreover, Myc represses the Serum Response 
Factor (SRF)-responsive genes, leading to a pro-apoptotic effect (Wiese et al., 
2015). 
• Cell adhesion/cytoskeleton: Myc down-regulates the expression of genes 
encoding for collagen, adhesion (β1-integrin, N-cadherin) and cytoskeletal 
proteins (Actin, Cdc42) (Coller et al., 2000; Gebhardt, 2006; Herkert et al., 
2010; Shiio et al., 2002). This may affect cell morphology, enhance anchorage-
independent growth and cause mobilization of stem cells from their niche, all 
functions that are tightly linked to the transforming potential of Myc (discussed 
below). 
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1.3.1 Myc and Miz1: functions and role in tumorigenesis 
The Myc-interacting zinc finger protein1 (Miz1), encoded by the Zbtb17 gene, is a 
transcription factor of the POK (Poxvirus and Zinc finger (POZ) and Krüppel) 
family (Peukert et al., 1997). The Zbtb17 gene encodes for a protein of 297 
residues and molecular mass of 32.5 kDa. The N-terminus of Miz1 protein 
contains a POZ/BTB (POZ/Broad complex, Tramtrack, Bric à brac) domain 
(Costoya, 2007; Stogios, Downs, Jauhal, Nandra, & Privé, 2005) (Figure 3). This 
region is essential for homo- and hetero- oligomerization, enabling the formation of 
dimers and tetramers in solution (Stead et al., 2007); moreover, it allows the 
recruitment of non-POZ proteins, the association to the chromatin and the 
fulfilment of the transcriptional functions (Kelly & Daniel, 2006). Indeed, deletion of 
the POZ domain dampens Miz1 binding to DNA (Gebhardt et al., 2007; Kosan et 
al., 2010). The central region of Miz1 protein consists in a Transactivation (TA) 
Domain and 13 consensus Cys2Hys2 Krüppel-type zinc finger domains (Peukert et 
al., 1997; 1997). This region is also involved in mediating Miz1 binding to DNA, 
which happens preferentially to a long non-palindromic sequence placed close to 
the transcriptional start site (TSS) of the regulated genes (Barrilleaux et al., 2014). 
 
 
 
 
Figure 3: Miz1 structure. Schematic representation of Miz1 protein, it contains: a BTP/POZ domain 
(essential for oligomerization, association to the DNA and fulfilment of the transcriptional functions), a 
transactivation (TA) domain and 13 Zinc Fingers (ZnF) domains (functional to DNA interaction) (modified from 
Wiese et al. 2013). 
 
Miz1 can interact with different partners and, depending on that, the transcriptional 
effect can vary. In particular: Miz1 activates transcription when associated with the 
histone acetyltransferase p300 and nucleophosmin (Staller et al., 2001; Wanzel et 
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al., 2008); whereas it plays a repressive function when in conjunction with Myc 
(Peukert et al., 1997), Bcl-6 (Phan, Saito, Basso, Niu, & Dalla-Favera, 2005), Gfi1 
(Q. Liu, Basu, Qiu, Tang, & Dong, 2010) or Zbtb4 (Weber et al., 2008). In 
particular, the Myc/Max dimer displaces Miz1 co-activators and/or recruits co-
repressors (DNA methyltransferases, Histone Deacetylases) thus blocking the 
positive effect of Miz1 on the transcription of its target genes (Brenner et al., 2005; 
Varlakhanova, Cotterman, Bradnam, Korf, & Knoepfler, 2011) (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Myc/Max/Miz1 and transcriptional repression. Miz1 alone activates transcription by interaction 
with the histone acetyltransferase p300/CBP (CREB-binding protein) and nucleophosmin (NPM). Associating 
with Myc/Max, Miz1 plays a repressive function. Indeed, Myc/Max dimer displaces Miz1 co-activators and/or 
recruits co-repressors (e.g. Histone Deacetylase 3 (HDAC3), DNA (cytosine-5)-methyltransferase 3a 
(Dnmt3a), Alternate reading frame protein (Arf)) to repress the transcription (from Herkert et al., 2010). 
 
The Myc/Miz1/Max trimer down-regulates the transcription of two groups of genes: 
proliferation/survival genes and cell adhesion-related genes. The first group 
includes p15INK4B (Staller et al., 2001), p21CIP1 (Steffi Herold et al., 2002), p27 KIP1 
(Yang et al., 2001), p57KIP2 (Hönnemann, Sanz-Moreno, Wolf, Eilers, & Elsässer, 
2012), proteins involved in cell cycle arrest and reduction of cell proliferation. For 
example, TGFβ induces p15INK4B expression by promoting binding of its effectors 
Smad3/4, Miz1 and Sp1 upstream of the promoter while Myc/Max binding to Miz1 
Copyright © 2010 The Author(s) 
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block it (Seoane et al., 2001). A similar mechanism happens on the p21CIP1 
promoter, where upon UV irradiation and after release of the interacting 
topoisomerase II binding protein 1 (TopBP1), Miz1 activates the gene transcription 
ensuring DNA damage-induced cell cycle arrest. Myc binding to Miz1 blocks 
p21CIP1 expression, switching the cell cycle arrest response to apoptosis (Steffi 
Herold et al., 2002). In fact, Miz1 plays a central role also in the regulation of Myc-
mediated apoptosis, as shown by the dampening of the apoptotic response in cells 
that overexpress a form of Myc unable to bind Miz1 (the MycV349D mutant, 
hereafter MycVD) (Steffi Herold et al., 2002) compared with cell overexpressing 
wild type Myc (Patel & McMahon, 2006) (Figure 5). Indeed, Miz1 alone up-
regulates the transcription of the pro-survival gene Bcl2, but together with Myc 
represses Blc2, thus favouring apoptosis (Patel & McMahon, 2007). 
The Myc/Miz1/Max complex represses also a second class of genes coding for 
molecules involved in cell-cell adhesion, actin cytoskeleton and interaction with the 
extracellular matrix (Gebhardt, 2006). For example, in either keratinocytes or 
hematopoietic stem cells, the repression of integrin-coding genes by Myc is Miz1-
dependent and influences the interaction of the stem cells with the stem niche 
(Gebhardt, 2006; Wilson, 2004) (discussed below). 
Recent genomic studies pointed out the complexity of Myc and Miz1 interaction in 
transcriptional regulation. In particular, in primary cells Miz1 has been shown to 
bind a small set of target genes, mainly involved in vesicular transport, 
endocytosis, lysosomal biogenesis, cell-cell contact, cell differentiation and growth 
(Gebhardt et al., 2007; Kosan et al., 2010; E. Wolf et al., 2013a; Ziegelbauer, Wei, 
& Tjian, 2004). Almost all the promoters of these genes contain the Miz1-binding 
motif (Barrilleaux et al., 2014) and comparison between different models (murine 
neural progenitor cells and human mammary epithelial cells) showed that the 
binding sites of Miz1 are conserved between different species and cell type (E. 
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Wolf et al., 2013a).On the other hand, in tumor cells, in which Myc levels are high, 
Miz1 is targeted by Myc also to new binding sites (containing E-box but not only) 
(Walz et al., 2014). The transcriptional output of the concerted binding of the two 
proteins to promoters seems to be governed by their relative amount: for Myc-
activated genes Myc quantity is higher than Miz1, for Myc-repressed genes it is 
similar. 
Depletion of Miz1, mediated by shRNA, has been described to promote de-
repression of a large part (25-40%) of Myc down-regulated genes, while having no 
effect on Myc activated genes (Walz et al., 2014). A similar result can be observed 
when the mutant Myc VD (unable to bind Miz1) is overexpressed instead of wild 
type Myc: impairment in gene repression and no effect on gene activation (Walz et 
al., 2014).  
Multiple data in vivo suggested that Miz1 could be crucial in Myc-dependent 
tumorigenesis (Wiese et al., 2013). Indeed, Myc VD overexpression in murine 
transgenic models strongly delays lymphomagenesis compared to Myc WT up-
regulation, with a reduced cell growth and enhanced TGFβ–induced senescence 
(Möröy, Saba, & Kosan, 2011; Müller et al., 2014; van Riggelen et al., 2010). In 
addiction, Myc/Miz1 repression of p15INK4B and p21CIP1 expression, in response to 
stimuli that enhance proliferation, have been shown to support skin papilloma 
formation (Hönnemann et al., 2012; Inoue et al., 2013), as well colon 
carcinogenesis (Wiese et al., 2013). 
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Figure 5: Myc/Miz1 functions. Miz1 induces transcription of its target genes (e.g. p21CIP1), while Myc 
antagonizes the process binding Miz1 and inducing repression of these targets. Myc VD (Herold et al., 2002), 
a Myc mutant impaired in Miz1 binding, loses Miz1-dependent transcriptional repression (from Moroy et al, 
2011). 
 
1.4 Mammary Epithelial Cells (MECs) 
The mammary gland is an organ developed as an appendage of the skin, a large 
and complex glandular system capable to produce nutrient-rich secretions. It has 
been thought to derive from an apocrine-like skin gland (Oftedal, 2002) that, by 
secreting milk, has developed during evolution to allow nutrition and microbial 
protection to the offspring (Peaker, 2002). 
The mammary gland is organized in two compartments: the epithelium and the 
stroma. The epithelium is formed by ducts (that transport the milk) and alveoli 
(spherical structures). Two types of cells surrounding a lumen constitute these 
structures: the luminal cells, that in the alveoli are specialized to produce milk, and 
the basal cells, which constitute the myoepithelial contractile component. The 
stroma, surrounding and supporting the epithelial structures, is constituted mostly 
by adipocytes, but also fibroblasts, haematopoietic cells and blood vessels 
(Hennighausen & Robinson, 2005) (Figure 6). 
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Figure 6: Schematic structure of the mammary gland ducts. Two types of cells surrounding a lumen make 
the epithelium of the mammary ducts: the luminal cells and the myoepithelial cells. The supporting stroma is 
constituted mostly by adipocytes, fibroblasts, haematopoietic cells and blood vessels (from Visvader, 2009). 
 
The mammary gland is a highly dynamic tissue, which undergoes extensive 
cellular remodelling and morphological changes throughout life, in particular during 
puberty and pregnancy (Hennighausen & Robinson, 2005). Mammary stem cells 
(MaSCs) are fundamental both in the organogenesis and in the homeostatic 
maintenance of the mammary gland. The MaSCs are a small pool of cells (<5%) in 
the mammary epithelium, displaying stem cells features such as capacity of multi-
lineage differentiation and self-renewal. The MaSCs generate the mature 
mammary epithelium, giving rise to either the luminal or the myoepithelial lineage 
through different lineage-restricted intermediates (Visvader, 2009). 
Two main models have been proposed to explain the differentiation hierarchy 
within the mammary gland epithelium (P. A. Joshi & Khokha, 2012; Visvader & 
Smith, 2011). The first scenario suggests the existence of a multipotent stem cell 
able to generate both luminal (ductal or alveolar) and myoepithelial differentiated 
cells (Stingl et al., 2006). A strong evidence in support of this model is the 
demonstration that a single basal cell, can generate an entire and functional 
mammary gland contributing to both luminal and myoepithelial lineage (Shackleton 
et al., 2006). The second scenario distinguishes between basal and luminal 
Copyright © 2009 Cold Spring Harbor Laboratory Press 
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unipotent stem cells, which differentiate in a lineage-restricted way. Indeed, 
lineage-tracing experiments demonstrated the existence of unipotent stem cells in 
the postnatal and adult epithelium. These cells would be able to maintain either 
the luminal or the basal epithelial populations but not both. According to this 
model, multipotent stem cells, with higher self-renewal ability, would be present 
only in puberty, pregnancy or in case of tissue regeneration and transplantation 
assay, not in normal tissue maintenance (Van Keymeulen et al., 2011) (Figure 7). 
	  
 
Figure 7: Schematic representation of epithelial cell hierarchy in the mouse mammary gland. Two 
different models explain the hierarchy within the mammary gland epithelium. The first one proposes the 
existence of one true multipotent stem cell, able to generate both luminal and myoepithelial differentiated cells 
through descendent progenitor cells, that could be both long- and short- lived lineage restricted cells. The 
alternative scenario suggests the presence of unipotent stem cells: luminal‐stem cell (Lum‐SC) and 
myoepithelial‐stem cell (Myo‐SC), in addiction to the pregnancy-stem cells (Preg-SC, emerging only during 
pregnancy). In this case, real multipotent stem cells would be present only in puberty or recruited in case of 
wound healing/tissue regeneration, not in mammary gland homeostasis (from Lindeman & Visvader, 2011). 
 
The relationship between multipotent and unipotent stem cells could be better 
clarified by unifying the experimental methods used for identification and isolation 
of MaSCs. One of the first methods used was based on morphological analysis by 
electron microscopy. It evidenced the presence of Small Light Cells (SLCs) in the 
basal layer, constituting the 3% of the epithelial population and having properties 
that resemble those of the stem cells (Chepko & Smith, 1997). Since then, new 
Copyright ©2011 European Molecular Biology Organization 
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methods have been developed to study and functionally characterize putative 
stem cells. In vitro one of the most used clonogenic assays is the growth of cells in 
non-adherent conditions in which only stem cells can grow and give rise to a new 
colony, called mammosphere (Debnath & Brugge, 2005; Dontu & Wicha, 2005; 
Dontu et al., 2003). In vivo instead, to evaluate self-renewal capacity, the most 
used technique is the serial dilution transplantation. In this case, the putative stem 
cells are transplanted in serial dilutions into the cleared fat pad of syngeneic or 
immunodeficient host mice and the frequency of mammary stem cells is calculated 
on the basis of positive reconstitution (evaluated by the presence of branched 
ductal trees with lobules and/or terminal end buds) (Deome et al., 1959; Illa-
Bochaca et al., 2010; Makarem et al., 2013). Currently, the most commonly used 
methods to fractionate the epithelial compartments and isolate potential stem cells 
are based on staining of surface markers, clonogenic assays, specific enzymatic 
activity and dye-retention (Cicalese et al., 2009; Dontu et al., 2003; Ginestier et al., 
2007; Stingl, Eaves, Zandieh, & Emerman, 2001; Visvader, 2009). 
Great efforts have also been made to understand which mechanisms and 
pathways are involved in the maintenance and function of MaSCs. In particular, 
several genomic studies focused on the characterization of the specific 
transcriptional programs active in the different epithelial subpopulations (Kendrick 
et al., 2008; Lim et al., 2009; 2010; Sheridan et al., 2015). Multiple pathways have 
been discovered to play an essential role in governing stem cells status, including 
steroid hormones, Notch, BMP/TGFβ, Wnt/β-catenin, and JAK-STAT signaling 
(Fridriksdottir, Petersen, & Rnnov-Jessen, 2011; Fuchs, Tumbar, & Guasch, 
2004). In general, the microenvironment surrounding the stem cells, commonly 
named “niche”, is pivotal in providing the adequate stimuli to either keep the ability 
to self-renew or to direct the fate through a complex repertoire of differentiation 
programs (Manavathi, Samanthapudi, & Gajulapalli, 2014; Visvader, 2009; 
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Visvader & Smith, 2011). Indeed, in the niche, specialized differentiated cells 
secrete specific factors and interact with the extracellular matrix (through 
cadherins, adherent junctions and integrins) such as to determine the retention or 
the release, and subsequent differentiation, of the stem cells (Fuchs et al., 2004). 
1.4.1 Mammary Cancer Stem Cells (CSCs) 
The stem cell concept has been applied also to tumors. Through the dissociation 
and transplantation of human cancer cells into immune-deficient mice, a 
subpopulation of cells capable of tumor reconstitution has been identified (Reya, 
Morrison, Clarke, & Weissman, 2001), which led to the so-called cancer stem cells 
hypothesis. This posits the existence of a minor population of self-renewing cancer 
stem cells (CSCs) able of reconstitute tumors upon transplantation (Kreso & Dick, 
2014). These cells, which have been extensively characterized, comprise the 1-
10% of the total population and are identified in human tumors by specific patterns 
of surface markers (CD44+, CD24-/low), as well as by high ALDH enzymatic activity 
(Groner, Vafaizadeh, Brill, & Klemmt, 2009). CSCs may generate through 
mutational events in normal stem cells or progenitors, which allows unlimited 
propagation of these cells and tumor maintenance (Cobaleda, Cruz, González-
Sarmiento, Sánchez-García, & Pérez-Losada, 2008). Indeed, the cancer stem 
cells acquire the ability to symmetrically divide in two cells able to self-renew; 
while, usually the stem cells divide asymmetrically generating a stem cell and a 
cell undergoing to differentiation (Morrison & Kimble, 2006). 
Experimental observations showed that acquisition of a more migratory phenotype 
due to epithelial to mesenchymal transition (EMT) is also associated with the 
appearance of stem cells properties, increasing the number of self-renewing cells 
able to seed mammospheres and, when implanted into cleared fat pads, to give 
rise to the entire epithelial tree (Mani et al., 2008). In fact, human mammary 
epithelial cells (HMECs) can generate SCs upon activation of pathways driving 
 32 
EMT such as the Ras-MAPK cascade, Twist, Snail, Slug (Wenjun Guo et al., 
2012; Mani et al., 2008; Morel et al., 2008). Several stimuli such as hypoxia, 
growth factors, cytokines and all the elements of the microenvironment of the stem 
niche can shape the mammary epithelial cells and let them acquiring stem cells 
features. However, this theory has recently been reformulated in the light of 
observations suggesting that distinct EMT programs govern normal and cancer 
stem cells (Ye et al., 2015). 
Two main hypotheses have been formulated to explain the contribution of CSCs to 
the tumor formation and characteristics (Cobaleda et al., 2008). The first model 
considers the grade of differentiation of the initiating cells as the main factor that 
shapes the final tumor subtype (Ince et al., 2007). The second model proposes 
that all the tumor subtypes derive from the same cancer stem cell, which could 
then partially undergo differentiation and, through a random combination of 
oncogenic events, determines the tumor phenotype (Tsai et al., 1996). 
According to transcriptional profiling experiments of mammary subpopulations and 
tumors, a transcriptional similarity between the different tumors subtypes and 
specific epithelial subpopulations has been observed (Figure 8). In particular, 
Claudinlow and ‘Normal-like’ tumors, having mesenchymal features, show a 
signature similar to the MaSCs subset. Surprisingly, the poorly differentiated 
basal-like tumors share more similarity with the luminal progenitors than the 
MaSCs. As expected, the signature of the more differentiated tumor subtypes 
Luminal A and B is similar to the differentiated luminal cells. Finally, the HER2-
overexpressing tumors don’t show a clear association with a normal counterpart of 
epithelial cells, but probably derive from cells with a luminal predisposition (Granit, 
Slyper, & Ben-Porath, 2013; Visvader, 2009). Hence elucidating the structure of 
the normal mammary epithelial hierarchy shall be functional to understand the 
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cellular origins of the different tumor subtypes and to shed light on the causes of 
breast cancer heterogeneity (Skibinski & Kuperwasser, 2015). 
The presence of the CSCs may also explain the differential sensitivity to 
conventional therapies (chemo- and radio- therapy) and the relapse events of 
some breast tumors. Indeed, these cells are dormant or slow-cycling and 
mutagenic events alter their expression of multi-drug transporters, growth factors 
and anti-apoptotic signals. All these features allow the CSCs persistence after the 
cancer therapies. Actually these treatments, targeting the rest of the tumor, cause 
the selection of the CSCs and their increase in proportion in the total cancer mass. 
This results in the regeneration of the tumor, once the therapies are suspended 
(Kakarala & Wicha, 2008; Mimeault, Hauke, Mehta, & Batra, 2007). 
Altogether, the above observations indicate that eradication of the cancer stem 
cells, by induction of their differentiation or apoptosis, would be essential to 
definitively cure breast cancer. Given the recent demonstration that distinct 
programs govern the normal and the cancer stem cells (Ye et al., 2015), a better 
knowledge of the pathways that specifically control cancer stem cells is needed to 
design new treatment strategies able to specifically target CSCs without causing 
toxicity to normal stem cells (Mimeault et al., 2007). 
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Figure 8: Model of human mammary epithelium hierarchy and potential derivation of breast tumor 
subtypes. According to data obtained with transcriptional profiling, six mammary tumor types (Claudinlow, 
Normal-like, Basal, Lumina A, Luminal B, HER2-overexpressed) have been associated to the normal epithelial 
cell counterpart (MaSCs, luminal progenitors or mature luminal cells) (from Visvader, 2009). 
 
1.5 Myc: role in balancing differentiation and self-renewal  
The inhibition of differentiation was one of the first biological activities attributed to 
c-myc oncogene (Coppola & Cole, 1986; Prochownik & Kukowska, 1986). This 
function has been confirmed by Myc gain/loss of function studies in cell lines and 
primary tissues of heterogeneous origin (Leon, Ferrandiz, Acosta, & Delgado, 
2014), leading to the concept that inhibition of differentiation is a critical 
mechanism in Myc-mediated tumorigenesis. 
Myc dampens differentiation mainly by preventing the exit from the cell cycle, 
(Buttitta & Edgar, 2007; Oster et al., 2002). Furthermore, Myc antagonizes the 
transcriptional function of Mxd or Mad proteins (Mad 1-4, Mnt), that dimerizing with 
Max causes the inhibition of proliferation and apoptosis, favouring cell 
Copyright © 2009  Cold Spring Harbor Laboratory Press 
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differentiation (Zhou & Hurlin, 2001). Lastly, MYC inhibits the expression of 
transcription factors that are in charge of driving differentiation in different tissues. 
For example it blocks c-JUN, GATA1, C/EBPα, ERG1, ‘master regulators’ of 
neuronal, erythroid, adipocytic and macrophagic differentiation, respectively (Leon 
et al., 2014). 
Beyond its role in inhibition of cell differentiation, Myc plays an active role in 
promoting stemness. Expression of c- and N- myc is pivotal in embryonic stem 
cells (ESCs). Gene expression signatures have highlighted that the Myc 
transcriptional program is highly expressed in these cells (Ben-Porath et al., 2008) 
and accounts for the higher similarity between ESCs and cancer cells (Kim et al., 
2010). 
The network by which Myc can contribute to the maintenance of pluripotency and 
ESCs identity is complex. Myc induces the expression of Polycomb repressive 
complexes components or activates microRNA (e.g. miR-17-92), able to repress 
genes involved in cell differentiation (C.-H. Lin, Jackson, Guo, Linsley, & 
Eisenman, 2009; Neri et al., 2012). Finally, it represses developmental genes such 
as Gata6 or the Hox cluster interacting with the NuRD and the CoREST 
complexes (Chappell & Dalton, 2013). 
Yamanaka and colleagues established pluripotency in vitro using Myc, together 
with Oct4, Sox2 and Klf4 (OSKM) and reprogrammed a differentiated somatic cell 
to an induced pluripotent stem cell (iPSC) (Takahashi & Yamanaka, 2006). Many 
variations to the initial approach have been described. Some of them showed that 
Myc overexpression is not essential in establishing pluripotency (Nakagawa et al., 
2007), however it has been demonstrated that its lack reduces the efficiency and 
delays the reprogramming. It seems that OSK have a pioneer activity in binding 
closed chromatin, whereas Myc enhances OSK binding to the DNA (Soufi, 
Donahue, & Zaret, 2012). 
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Despite all these evidences corroborating the role of Myc in self-renewal and 
against differentiation, there are as many models where Myc plays a pro-
differentiation role. Hematopoietic stem cells (HSCs) are one of the best-
characterized systems in which Myc plays a pivotal role in homeostasis. Indeed, 
Myc deletion produces expansion of HSCs, whereas Myc overexpression causes 
depletion of the stem cell pool. This is due to Myc activity in regulating adhesion 
properties within the stem cell niche. As a matter of fact, Myc down-regulates 
integrins and N-cadherin expression, allowing the release of the stem cells from 
their protective microenvironment and anticipating the HSCs differentiation 
(Wilson, 2004). 
The skin epidermis is another model in which Myc over-expression promotes 
differentiation (Gandarillas & Watt, 1997; Watt, Frye, & Benitah, 2008). Myc is 
expressed in the proliferative basal layer and in the bulge, its up-regulation 
modifies the adhesion properties (decreased α6β4 integrin expression), causes 
the formation of hemidesmosomes and the assembly of actinomyosin cytoskeleton 
(Frye, 2003). These changes of the local microenvironment stimulate 
keratinocytes stem cells progression to transient-amplifying cells, promoting 
differentiation along the epidermal and sebaceous lineages (Arnold & Watt, 2001). 
The mechanisms of action of Myc in mammary epithelial stem cells and their 
microenvironment are still incompletely characterized. Both basal cells and luminal 
progenitors express high levels of Myc (Kendrick et al., 2008). Myc deletion in 
progenitor alveolar cells delays their differentiation and proliferation in pregnancy, 
decreasing also the expression of proteins involved in milk synthesis, during 
lactation (Stoelzle, Schwarb, Trumpp, & Hynes, 2009). Instead, Myc deletion from 
the basal cells leads to gland hypoplasia, reduces the proliferation rate both in 
luminal and basal epithelial compartments (suggesting a control of the luminal 
compartment by the basal cell layer), affects the self-renewal ability of the stem 
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and progenitor cells present in the basal layer impairing both their clonogenic 
potential in vitro and their reconstitution efficiency in vivo (Moumen et al., 2012). 
On the other side, Myc up-regulation in mammary epithelial cells causes 
mammospheres amplification and increased frequency of cleared fat pad 
repopulation (Pasi et al., 2011). All these observations highlight the role of Myc in 
expanding the mammary stem and progenitor compartments, even if remains still 
unclear where Myc exerts its function (luminal or basal compartment) and if it 
changes during the developmental stages of the mammary gland and/or in 
pathological conditions. 
To understand the function of Myc in the mammary gland, and in particular in the 
self-renewing population, could be functional also to the comprehension of its role 
in breast cancers. In human, MYC oncogenic activity is associated with an 
aggressive tumor phenotype (BRCA1 alterations, ER-negativity, basal-like 
subtype) and poor prognosis (Blancato, Singh, Liu, Liao, & Dickson, 2004; Y. 
Chen & Olopade, 2008). In murine models, Myc up-regulation in the mammary 
glands raises the incidence of cancer, even if it needs the cooperation with other 
oncogenes (H-Ras being the most common) (Cowling, D'Cruz, Chodosh, & Cole, 
2007; Schoenenberger et al., 1988). Several processes could underline the Myc-
enhanced tumorigenesis, for example it has been observed that abnormal 
activation of Myc can lead to breast oncogenesis reinforcing β-catenin-dependent 
amplification of stem cells (Moumen et al., 2013) or inducing anchorage-
independent growth and a general morphological transformation of mammary 
epithelial cells (Cowling et al., 2007). Anyhow, Myc deregulation, not only leads to 
the acquisition of a malignant stem cell-like phenotype (R. Nair et al., 2014), but it 
impacts also on processes related to survival, proliferation, apoptosis and genome 
instability in mammary epithelial cells (Hynes & Stoelzle, 2009; Pasi et al., 2011; 
Wang et al., 2011). 
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Myc has been shown to either promote or be required for epithelial to 
mesenchymal transition (EMT) both in vitro and in vivo (Bin Cho, Cho, Lee, & 
Kang, 2010; Jackstadt et al., 2013; A. P. Smith et al., 2008; Trimboli et al., 2008), 
supporting a migratory cellular phenotype in breast. Nevertheless, the effects of 
Myc on migration are not univocal and depend on cell-type or context (Cappellen, 
Schlange, Bauer, Maurer, & Hynes, 2007; H. Liu et al., 2012). Gene expression 
profiles in mammary tumors showed that Myc, like Ras, is able to induce features 
associated to EMT and cancer stem cell (M. Liu et al., 2009). The repression of 
the extracellular matrix proteins (fibronectin and collagen), reduced adhesiveness, 
cytoskeletal dysregulation are all hallmarks of Myc cell transformation (Akeson & 
Bernards, 1990; Coller et al., 2000; Cowling & Cole, 2007; Elkon et al., 2015; Shiio 
et al., 2002). 
In general, Myc is a key transcription factor in the genesis of tumor. Also in other 
cellular systems, its down-regulation can cause senescence, loss of tumor-
initiation capability and a general impairment of the neoplastic features (Akita et 
al., 2014; Civenni et al., 2013; Shachaf et al., 2004). In tumorigenesis, the 
regulation of self-renewal can be one crucial activity of Myc. Indeed, if 
physiological level of Myc are fundamental in stem cell maintenance, its up-
regulation can support the formation of cancer stem cells (Laurenti, Wilson, & 
Trumpp, 2009) (Figure 9). Since inactivation of Myc is often associated to cell 
differentiation and regression in Myc-addicted tumors, the future challenge will be 
to identify a way to make its complex pathway druggable also in breast cancer. 
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Figure 9: Role of Myc in differentiation of stem cells. The quiescent stem cells keep the tissue 
homeostasis in standard conditions. When activated, Myc (physiological levels) induces stem cells self-
renewal, this process ensure both stem cells pool maintenance and transient-amplifying/progenitors cells 
production. The latter cells extensively proliferate before terminal differentiation into mature cells. During these 
phases, Myc inhibits terminal differentiation and has an essential role in proliferation. However, in some 
tissues at this stage, Myc can also regulate the release from the stem cell niche, thus differentiation. Transient 
reintroduction of Myc, in cooperation with Oct4, Sox2 and Klf4, induces reprogramming of somatic cells into 
pluripotent stem cells. Finally, deregulated Myc activity can, in association with other oncogenic events, 
induce the formation of Cancer Stem Cells (CSCs) (from Laurenti et al., 2009). 
 
1.6 Aim of the project 
The role of Myc in transcriptional repression is still one of the controversial aspects 
of Myc biology. Contrasting data and interpretations have led to debate even the 
existence of a Myc-dependent repressive function (Nie et al., 2012). To clarify this 
aspect of Myc transcriptional regulation is a crucial point, given the previous 
observations about its involvement in cell adhesion, self-renewal, survival and 
other functions central in tumorigenesis. 
Unquestionably, Myc plays a pivotal role in balancing self-renewal and 
differentiation, but the fact that in different tissues the outcomes of Myc 
deregulation are different is a confounding factor. Although Myc is one of the key 
players in self-renewal function, its role in mammary epithelial stem cells is still 
Copyright © 2009 Elsevier Ltd.  
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unclear. The goal of this study was to understand the role of Myc in transcriptional 
regulation of mouse mammary epithelial cells (MMECs) by genome-wide analysis. 
Taking advantage of a Myc mutant (Myc VD), unable to bind Miz1 (Steffi Herold et 
al., 2002), we specifically investigated the role of the Myc/Miz1 complex in 
controlling stem cells properties and the balance between self-renewal and 
differentiation. This could be clinically relevant for breast cancer patients, in which 
deregulation or overexpression of MYC are common features (about 20% of the 
cases) (Liao & Dickson, 2000), especially if we consider the relevance that 
Myc/Miz1 complex showed in other contexts of tumorigenesis (Wiese et al., 2013). 
In breast tumors, MYC can promote invasiveness and metastasis formation 
(Wolfer et al., 2010), its oncogenic activity is associated with more aggressive 
tumors and a poorer prognosis (Blancato et al., 2004; Y. Chen & Olopade, 2008). 
We thus decided to understand if Miz1 could play a role in these processes. 
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2. Material and Methods 
 
2.1 Mouse models and genotyping 
The following mouse strains were used for this study: c-mycfl/fl mice (Trumpp et al., 
2001), R26-MycERT2 mice (Murphy et al., 2008), TET-MYC WT and TET-MYC VD 
mice (van Riggelen et al., 2010), R26rtTA mice (Jansson & Larsson, 2012), 
MMTVrtTA mice (Jackson lab, Stock #010576) (Whisenhunt et al., 2006), 
AthymicNude-Foxn1nu (Harlan). c-mycfl/fl, R26-MycERT2 , R26rtTA and MMTVrtTA 
mice were maintained on a C57/Bl6 background. TET-MYC WT and TET-MYC VD 
mice were on a FVB background. Mice obtained from combination of strains in 
different background were used only at the first generation, in order to keep the 
genetic composition constant. 
Primers used for genotyping are listed in Table 1. 
 
Strain Primers 
c-mycfl/fl CACCGCCTACATCCTGTCCATTC 
TACAGTCCCAAAGCCCCAGCCAAG 
R26-MycERT2 
AAAGTCGCTCTGAGTTGTTAT (comm.) 
GCGAAGAGTTTGTCCTCAACC (WT) 
GGAGCGGGAATGGATATG (KI) 
TET-MYC WT 
GGCGCTGCGTAGTTGTGCTGATGT 
AGCCCCGAGCCCCTGGTG 
TET-MYC VD 
CTGCTGCCAAGAGGCTCAAG 
GTATGCTGTGGCTTTTTTAAGGATAT 
R26rtTA 
AAAGTCGTCCTGAGTTGTTAT (comm.) 
GCGAAGAGTTTGTCCTCAACC (WT) 
GGAGCGGGAGAAATGGATATG (KI) 
MMTVrtTA GGCGAGTTTACGGGTTGTTA 
CTGGTCATCATCCTGCCTTT 
 
Table 1: Primers used for mouse genotyping. A common primer (comm.) and a specific one were used to 
discriminate between wild type (WT) and knock-in (KI) mice. 
 
Experiments involving animals were performed in accordance with the Italian laws 
(D.L. 116/92 and following additions), which enforce EU 86/609 directive (Council 
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Directive 86/609/EEC of 24 November 1986 on the approximation of laws, 
regulations and administrative provisions of the Member States regarding the 
protection of animals used for experimental and other scientific purposes). 
 
2.2 Mammary gland dissection 
The thoracic (5th and 6th gland pair) and inguinal (7th and 8th gland pair) mammary 
glands of 6- to 12-week-old virgin mice were dissected to obtain primary mouse 
mammary epithelial cells (MMECs). Inguinal mammary glands were collected also 
for whole-mount staining and histology. Figure 10 is a schematic representation of 
the murine mammary glands localization. 
 
 
Figure 10: Schematic representation of the anatomy of murine mammary glands. Mouse mammary 
glands, in total five pairs, are divided in two subgroups: thoracic (1st to 6th glands) and inguinal (7th to 10th 
glands). The 5th and 6th thoracic gland pair and the 7th and 8th inguinal gland pair are usually dissected to 
isolate murine mammary epithelial cells (modified from Murphy E.D., 1966). 
1 2
3 4
5 6
7 8
9 10
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2.3 Mouse Mammary Epithelial Cells (MMECs) 
2.3.1 Isolation and FACS analysis 
Primary MMECs were isolated from thoracic and inguinal mammary glands. 
Tissues were mechanically minced, then digested with 200 U/ml collagenase I 
(Sigma), 10 mg/ml hyaluronidase IV (Sigma) in DMEM/F12 medium (Lonza) in 
rotation at 37°C for 3 hr. The samples were washed with PBS and centrifuged at 
600 rpm for 5 min to enrich for mammary epithelial cells and organoids and 
eliminate stromal contamination. The organoids were further digested with 0.05% 
trypsin (Lonza) for 5 min and 5 mg/ml dispase (Stem Cell Technology) plus 100 
µg/ml DNase (Roche) for 5 min. The cells were then filtered through 40 µm cell 
strainers to obtain a suspension of single cells (Wenjun Guo et al., 2012). The cell 
suspension was then centrifuged at 1200 rpm, 5 min at 4°C. The pellet was gently 
resuspended in a mix 1:1 of PBS and ACK lysing buffer (Lonza) for 1 min at room 
temperature, to lyse the red blood cells. The lysis was then stopped by dilution of 
the ACK buffer with extra PBS, then the samples were centrifuged 1200 rpm, 5 
min, 4°C and resuspended in the culture medium. 
For adhesion cell cultures, cells were plated in DMEM/F12 medium (Lonza) 
supplemented with 5% North American FBS (Hyclone), 10 ng/ml EGF (Peprotech), 
4 mg/ml heparin (Hospira), 50 ng/ml cholera toxin (Sigma), 500 ng/ml 
hydrocortisone (Sigma), 5 µg/ml insulin (Roche), 50-100 I.U./ml penicillin, 50 to 
100 µg/ml streptomycin, 0.5 mM L-Glu, 25mM Hepes (Sigma). For suspension 
cells culture, cells were plated in low attachment plates (BD Falcon) previously 
coated twice with polyhema (Sigma) in MEBM medium (Lonza), 2% B27 
supplement (Life Technology), 10 ng/ml EGF (Peprotech), 10 ng/ml FGF 
(Peprotech), 4 mg/ml heparin (Hospira), 500 ng/ml hydrocortisone (Sigma), 5 
µg/ml insulin (Roche), 50-100 I.U./ml penicillin, 50 to 100 µg/ml streptomycin. 
The purity of the epithelial cells culture was assessed three days after seeding by 
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FACS analysis (MACSQuant® Analyzer 10, Miltenyi Biotec). Cells were stained on 
ice for 30 min and were all positive for the epithelial markers CD24 (eBioscience) 
and negative for not-epithelial markers such as CD31, Tert119 and CD45 
(eBioscience) (Table 3). 
2.3.2 Immortalization of primary MMECs  
Primary MMECs have been isolated from c-mycfl/fl and R26-MycERT2 mice in order 
to obtain epithelial cells in which we could modulate the levels of Myc. 
To get a more stable and homogenous culture, we immortalized the cells through 
p53 and Rb knock-down (Elenbaas et al., 2001; Karantza Wadsworth & White, 
2008) by infecting them with the MLS-shp53 (Hemann et al., 2003) and LentiLox-
shRb (Rubinson et al., 2003) viral vectors, respectively. Unlike the human 
counterpart, murine cells do not need the expression of the telomerase catalytic 
subunit to be immortalized, given the higher length of murine telomeres. Over a 
period of 4-6 weeks, both not/single-infected epithelial cells and contaminating 
cells died, whereas immortalized MMECs started growing. MMECs colonies 
showed typical cuboidal and packaged epithelial shape. About ten independent 
single cell clones were picked and characterized by real-time RT-PCR analysis 
with a selected panel of epithelial (E-cadherin, ZO-3) and mesenchymal (Vimentin, 
N-cadherin) markers (primers sequences in Table 2). Two clones have been 
selected from each preparation as biological replicates on the basis of their 
epithelial features both at morphological and gene expression levels. In regular 
tissue culture MMECs clones were kept at 50-70% confluence at 37°C, 5% CO2, 
5% O2 and split every 3-5 days, at 1:5 dilution. 
2.3.3 Modulation of Myc expression 
To achieve the knock-out of the c-myc gene, c-mycfl/fl immortalized MMECs were 
treated with 100 µg/ml TAT-Cre recombinant protein (in-house prepared) and 10 
µM chloroquine (Sigma) for two hours in Optimem medium (Invitrogen) and 
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harvested after 24 hours. The Cre recombinase is an enzyme of the bacteriophage 
P1 able to catalyse the site-specific recombination between two regions of DNA 
called LoxP sites. In this case the LoxP sites were present into the 3’ untranslated 
region and the Intron 1 of c-myc gene sequence, thus after the cut the genes is 
irreversibly excided from the genome and switched-off. The TAT peptide derived 
from HIV-TAT protein, containing a nuclear localization sequence, renders the 
TAT-Cre recombinant fusion protein cell membrane-permeant. 
The immortalized MMECs from R26-MycERT2 mice, suitable for Myc activation, 
express the MycER transgene from the ubiquitous Rosa26 locus. MycER encodes 
for a fusion protein between the ligand-binding domain of a mutant estrogen 
receptor (ER) and the Myc protein. The ER domain, without its intrinsic 
transactivation activity, responds to the synthetic steroid 4-hydroxytamoxifen 
(OHT). Hence, it maintains the chimeric MycER protein (that is constitutively 
expressed) inactive in the cytoplasm, until OHT is added to the culture and allows 
its translocation to the nucleus. 
R26-MycERT2 MMECs have been stimulated with 200 nM OHT (Sigma) or EtOH 
(control) for 24 hours, and then harvested. 
c-myc knock-out and activation were evaluated at DNA and/or RNA level by real-
time RT-PCR and at protein level by western-blot analysis. 
 
2.4 DNA extraction and analysis  
Total genomic DNA was purified by DNeasy Blood & Tissue Kit (Qiagen) following 
manufacturer’s instructions. 10 ng of DNA were then used for qPCR reactions with 
FAST SYBR Green master Mix (Applied Biosystems), the sequences of the 
primers used are listed in Table 2. 
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2.5 RNA extraction and analysis 
Total RNA was purified by RNeasy columns (Qiagen) and treated on-column with 
DNaseI (Qiagen). RNA quality was checked with the Agilent 2100 Bioanalyser 
(Agilent Technologies). Complementary DNA (cDNA) was produced using the 
reverse transcriptase ImPromII (Promega). 10 ng of cDNA were used for real-time 
PCR reactions with FAST SYBR Green Master Mix (Applied Biosystems), the 
sequences of the primers used are listed in Table 2. 
 
2.6 Protein extraction and analysis 
Cell extracts were lysed by RIPA buffer (20 mM Hepes at 7.5 pH, 100 mM NaCl, 5 
mM EDTA, 10% Glycerol, 1% Triton X-100, 0.1% SDS supplemented with 
protease inhibitors (Mini, Roche) and phosphatase inhibitors (0.4 mM Sodium 
Ortovanadate, 10 mM Sodium Fluoride), then sonicated. 30 µg of total cell 
extracts, quantified with the Protein Assay kit (Bio-Rad), were separated by SDS-
PAGE using 7.5% or 12% polyacrylamide gels (Bio-Rad). The proteins were then 
transferred to a nitrocellulose membrane by Trans-Blot Turbo Transfer System 
(BioRad) for 30 min (25V- 1.0 A). Membranes were washed in TBS-T (10 mM 
TrisHCl, 100 mM NaCl, 0.1% Tween at pH 7.4) and blocked with 5% milk in TBS-T 
for 1 hour, then immunoblotted over-night with the indicated primary antibodies 
(Table 3): c-Myc (Y69, Abcam) and Vinculin (V9264, Sigma). After incubation of 
the membranes with appropriate secondary antibodies (Table 3) for 1 hour at room 
temperature, chemiluminescent imaging was performed by ChemiDoc MP System 
(BioRad) using Western ECL reagent (Pierce). 
 
2.7 MMECs self-renewal and growth assays 
Wild type (Ctr), TET-MYC WT and TET-MYC VD mice were crossed with R26rtTA 
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mice and the resulting offspring used to isolate primary MMECs for 3D culture 
mammosphere assay. This is an inducible system in which the TetO sequence 
(containing a tetracycline responsive element, TRE) is placed upstream of the 
promoter regulating the transcription of the transgene (in this case human c-MYC 
WT or VD). The reverse tetracycline transactivator (rtTA) is able to bind the TetO 
operator only in the presence of the antibiotic Tetracycline or its analogues 
Doxycycline (Tet-On system). In this way, the expression of the transgene is 
reversibly activated. 
c-MYC up-regulation was evaluated at RNA level by real-time RT-PCR and at 
protein level by western-blot analysis. 
A clonal sphere-forming assay was used to evaluate the self-renewal capacity of 
MMECs, that consists in growing them in non-adherent conditions as 
mammospheres (Dontu et al., 2003). Primary MMECs, isolated as previously 
described, were grown in ultra-low attachment plates at concentration of 20000 
cell/ml in a serum-free mammary epithelial growth medium. In these conditions 
only stem cells can grow and give rise to a new colony, called mammosphere. 
After one week in culture mammospheres were collected and centrifuged at 300 
rpm for 5 min at room temperature (the low centrifuge speed allow the 
sedimentation only of the spheres and not of single cells). The spheres were then 
resuspended in a small volume of fresh medium and manually disgregated by 
pipetting and using a syringe (25G needle), then filtered through 40 µm cell 
strainers to obtain single-cells suspension. The cells were counted and seeded at 
the initial concentration, in the presence or in the absence of 2 µg/ml Doxycycline 
(Sigma) to induce c-MYC overexpression, as indicated in each experiment. 
The Growth Rate (GR) was calculated as the number of cells counted after 
mammospheres disgregation per number of cells seeded. 
To establish the Sphere Forming Efficiency (SFE), the cells were seeded in 
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MethoCult™ (Stem Cell Technology) diluted 1:1 in cell culture medium 
(supplemented with the relative growth factors). Cells were then counted by 4x 
magnification on EVOS® Digital Microscopes (Electron Microscopy Sciences) after 
one week. SFE was calculated by dividing the number of newly formed 
mammospheres (considering only the spheres with diameter bigger than 80 µm) 
for the number of cells seeded, and reported as percentage. 
To calculate the sphere size, for each sample ten microscopic fields were acquired 
and the area of the spheres was measured using ImageJ 1.43u software (NIH, 
USA) analysis, considering only the spheres with diameter bigger than 80 µm and 
> 0.2 circularity (to exclude the formation of mere aggregates).  
 
2.8 EdU cell proliferation assay 
To measure the percentage of MMECs in S phase, small mammospheres formed 
48 hours after seeding of single-cells (between the M2 and M3 passage) have 
been incubated with EdU (5-ethynyl-2'-deoxyuridine, a nucleoside analogue of 
thymidine) 10 nM for 1.5 hours and then fixed with 2% formaldehyde for 5 minutes 
at room temperature. Samples were stained using anti-EdU antibody according to 
the manufacturer’s instructions (Click-iT® kit for cell proliferation, Life Technology) 
and then incubated with propidium iodide over-night. The percentage of 
proliferating cells was assessed by FACS analysis (MACSQuant® Analyzer 10, 
Miltenyi Biotec). 
 
2.9 Annexin V apoptosis assay 
The presence of apoptotic cells was measured using Annexin V staining following 
the protocol of the Annexin V/Dead Cell Apoptosis Kit (Life Technology). Before 
the staining, small mammospheres formed 48 hours after seeding of cells between 
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M2 and M3 passages were mechanically isolated into single-cells. Annexin V 
labels apoptotic cells, while living cells remain unstained. Propidium Iodide (PI) 
staining (50 µg/ml in PBS for 5 min) marked the necrotic cells. The number of 
labeled dead cells was measured by FACS analysis (MACSQuant® Analyzer 10, 
Miltenyi Biotec). 
 
2.10 Cleared fat pad reconstitution assay 
To functionally measure the stem cell frequency of MYC WT and VD over-
expressing mammospheres we performed mammary reconstitution assays 
transplanting single cells obtained from Ctr, TET-MYC-WT and TET-MYC-VD 
R26rtTA mammospheres, harvested at 48 hours after seeding at M2 passage. 
These cells were then transplanted in serial dilutions (1000, 500, 100 cells) into 
the cleared fat pads of host mice. We decided to use AthymicNude-Foxn1nu mice 
(homozygous, Harlan) as recipients since the donor cells were obtained from 
mixed background mice, in order to avoid any immune reject response. Cell 
aliquots suspended in PBS containing 25% Matrigel (BD-Bioscience) were injected 
into the inguinal mammary fat pads of AthymicNude-Foxn1nu mice at 3 weeks of 
age, previously cleared of the endogenous mammary epithelium. Transplanted 
mammary fat pads were examined for gland reconstitution 12 weeks post-
injection. The presence of branched ductal trees with lobules and/or terminal end 
buds was considered as positive reconstitution. The frequency of Mammary Stem 
Cells (MaSCs) in the transplanted cell population was calculated through the serial 
dilution transplantation using the Extreme Limiting Dilution Analysis Program 
(http://bioinf.wehi.edu.au/ software/elda/index.html) (Wenjun Guo et al., 2012; Hu 
& Smyth, 2009). 
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2.11 Whole-mount carmine alum staining 
In order to visualize the ductal development of whole mouse mammary glands we 
performed carmine alum staining. Inguinal mammary glands (7th and 8th gland 
pair in Figure 10) were spread on a glass slide and fixed either in 4% 
formaldehyde (in case of subsequent IHC analysis) or ethanol/acetic acid (Sigma, 
in proportion 1:3) at room temperature over-night. They were washed in 70% 
EtOH for 30 min, rinsed in distilled water for 10 min and stained in carmine alum (1 
g carmine (Sigma), 2.5 g aluminum potassium sulfate (Sigma), 500 ml distilled 
water) at room temperature, until the white of the adipose tissue was not visible 
anymore. Then, the mammary glands were washed in 70%, 95% and 100% 
ethanol for 30 minutes each. Next, they were soaked in BABB solution 
(Benzylalcohol (Fluka): Benzylbenzoate (Sigma), 1:2), until fat pad clarifies. 
Mammary glands were photographed using a stereomicroscope (Olympus, 
SZX16) equipped with an Infinity 1 camera (Lumenera). 
 
2.12 Immunohistochemistry  
Formalin-fixed paraffin-embedded sections were deparaffinized in histolemon two 
times for 10 min each. The tissue sections were hydrated through graded alcohol 
series (100%, 95%, 70%, H2O), 5 min each, at room temperature. The antigen 
unmasking was done by citrate buffer (Biogenex), at pH 6 for 30 min at 99°C. After 
cooling, the slides were washed in water, then the quenching of endogenous 
peroxidases was performed in 3% H2O2 for 5 min at room temperature. After a 
wash in TBS (10 mM TrisHCl, 100 mM NaCl, 0.1%), the slides were pre-incubated 
with a blocking solution (Dako diluent solution) for 20 min at room temperature. 
The slides were incubated with primary antibody for 2 hours at room temperature 
(c-Myc (Y69, Abcam) or Ki67 (M7249, Dako), see Table 3, in Dako diluent 
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solution). After a wash in TBS, they were incubated with secondary antibodies 
(Table 3) for 30 minutes at room temperature. Then, they were washed in TBS 
and incubated in peroxidase substrate solution (DAB, Dako) for 10 min. The 
reaction was blocked in water, the tissue sections were counterstained with 
hematoxylin for 1 min. After rinsing with running tap water, the tissue sections 
were dehydrated through graded alcohol series and mounted with Eukitt. 
 
2.13 Murine tumor models 
To test the tumorigenic potential of MYC WT and VD overexpression in mice, we 
crossed MMTVrtTA mice and TET-MYC WT or VD mice. In this case, the rtTA 
protein is specifically expressed in the breast epithelia of the mammary ductal 
system under the control of the mouse mammary tumor virus (MMTV) promoter. In 
this way, we obtained an in vivo breast-specific conditional up-regulation of Myc 
WT and VD. Immediately after weaning (4-weeks), 6 mice for each experimental 
group were induced by Doxy diet (Mucedola Srl), a nutritionally complete diet 
containing Doxycycline (625 mg/kg). The induction of MYC expression (both WT 
and VD) and proliferation was monitored in immunohistochemistry by c-Myc and 
Ki67 (Table 3) staining respectively after one and three moths of induction by Doxy 
in two mice for each experimental group. At the same time points we also 
performed whole mount staining to verify any structural change in the mammary 
gland. TET-MYC mice without MMTVrtTA element induced as well by Doxycycline 
or TET-MYC/MMTVrtTA mice with standard diet were used as controls. Since the 
described latency for the tumor onset in TET-Myc MMTVrtTA mice is around 22 
weeks (D'Cruz et al., 2001), after one year the mice, that did not show any sign of 
tumor development, were sacrificed and the Lin- cells were analysed by FACS for 
CD49f (Biolegend) and Epcam (Biolegend) surface markers to monitor possible 
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changes in the cell type distribution of the epithelial compartment. 
 
2.14 RNA-seq analysis 
2.14.1 Library preparation 
Libraries for mRNA-seq were prepared from 2 µg of total RNA for the immortalized 
MMECs and 300 ng of total RNA for the primary mammospheres, using TruSeq 
RNA Sample Prep Kits v2 (Illumina) following manufacturer’s instruction. 
2.14.2 Data filtering and analysis 
RNA-seq libraries were sequenced in a 50 bp pair-end mode with 70 million reads 
depth. NGS reads were filtered using FASTX-Toolkit suite (fastq_quality_trimmer 
and fastq_masker tools, http://hannonlab.cshl.edu/fastx_toolkit/). Their quality was 
confirmed by FastQC application 
(www.bioinformatics.babraham.ac.uk/projects/fastqc/). RNA-seq NGS reads were 
aligned to the mm9 mouse reference genome, the corresponding gtf and bed files 
were downloaded from the UCSC Table Browser. The TopHat aligner (version 
2.0.6) with default parameter was used for the alignment. In case of duplicated 
reads, only one read was kept. Read counts were associated to each exon using 
the HTSeq software (http://www.htseq.org). Absolute gene expression was defined 
determining the number of exonic reads per kilobase per million of total reads 
aligned (eRPKM). Two-tailed Student’s t-test was used to calculate p-value; the p-
value adjusted (q-value) for multiple comparisons was obtained by Benjamini 
correction. Differentially expressed genes (DEGs) were identified using the 
Bioconductor package DESeq2 as genes whose q-value relative to the control 
sample is lower than 0.01. 
RNA-seq of c-mycfl/fl and R26-MycERT2 immortalized MMECs was performed on 
two biological replicates (independent clones, derived from a bulk population that 
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was a mix of cells isolated from five mice) and two technical replicates. RNA-seq 
of primary mammospheres was performed on three independent samples for each 
experimental group (each sample was a mix of cells isolated from five mice). 
 
2.15 Gene Ontology biological process analysis 
Functional annotation analysis to determine enriched Gene Ontology biological 
processes was performed using DAVID (Huang, Sherman, & Lempicki, 2008; 
2009). 
 
2.16 microRNA-seq analysis 
2.16.1 RNA extraction and library preparation 
Total RNA, including small RNA species was extracted using miRNeasy mini kit 
(Qiagen). 300 ng of total RNA, for each condition in biological triplicate, were used 
to prepare small RNA libraries using Illumina TrueSeqTM Small RNA kit following 
manufacturer’s instructions. The libraries were sequenced in 50 bp single-read 
mode at 20 million read depth on an Illumina Hiseq 2000 Platform. 
2.16.2 Data filtering and analysis 
After de-multiplexing by CASAVA software (that generates reads in FastQ format) 
and removing the adapters by the Flexible Adapter Remover software (FAR 
version 2.15), the reads of 22 bases (which correspond to miRNAs) were filtered. 
They were aligned to a custom genome that includes sequences of all canonical 
mature miRNAs (1975 mouse miRNAs according to the version 20 of miRBASE, 
http://www.mirbase.org) and the relative sequence variants or isoforms (named 
isomiRs). The isomiRs considered included the 5’- or 3’- end modified miRNA or 
the trimmed 3’- form. Reads shorter than 18 bp were discarded because 
considered unreliable. Alignment was performed with Bowtie ultrafast short-read 
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aligner (-v 0 alignment mode, no mismatches allowed). The number of aligned 
reads was counted by IsomiRage JAVA tool (Nicassio, 2014) 
(http://cru.genomics.iit.it/Isomirage/). The reads number was normalized for 
sequencing depth (standard reads per million normalization, RPM). The average 
expression in each experimental group was calculated between three biological 
replicates. Species with RPM >10 in at least one sample were selected for further 
analysis. miRNAs differentially regulated (|Log2 fold change|>0.5) were identified, 
with a p-value ≤ 0.05. Statistic analysis (Student’s t test) and heatmaps were 
realized by JMP 10 (SAS) software. 
 
2.17 Human tumors analysis 
In order to understand the relevance in human breast cancer of the genes 
identified differentially repressed between MYC WT and VD, we analysed their 
expression in a cohort of 1070 breast tumors present in the TCGA database (for 
which the MYC status is known). The tumors were divided in subcategories 
(Luminal A, Lumina B, Luminal unknown, Triple Negative Breast Cancer (TNBC), 
HER2+) on the basis of the available information about estrogen receptor (ER), 
progesterone receptor (PR), Epidermal Growth Factor receptor 2 (HER2) and Ki67 
expression (Voduc et al., 2010). The expression data were defined as Log2 fold 
change respect to the median of Normal breast tissue (112 sample). Out of 888 
genes identified in our signature, 754 had a clear human counterpart and were 
used for the analysis. A t-test analysis was used to define genes regulated in 
statistically significant way. 
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2.18 Analysis of published datasets 
Data from other published datasets (Kendrick et al., 2008; Lim et al., 2009; 2010; 
Sheridan et al., 2015; Stingl et al., 2006; Wiese et al., 2015) will been considered 
to select genes biologically significant from our Myc/Miz1 repressed genes list. All 
the expression data have been downloaded, from the supplementary tables of the 
paper or the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) 
database, as GSM matrix. The data will be normalized on the median of the 
control, if it is present a clear control, otherwise on the median of all the samples 
and expressed as Log2 fold change. Only those genes, of the Myc/Miz1 repressed 
signature, coherently regulated in each dataset (down-regulated in MaSCs vs. 
other subpopulations, down-regulated in CSCs vs. other tumors cells) will be taken 
into account. 
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Amplicon Forward primer Reverse primer 
RNA 
c-myc (mouse) TTTTTGTCTATTTGGGGACAGTG CATCGTCGTGGCTGTCTG 
c-MYC (human) CTGCGACGAGGAGGAGAACT GGCAGCAGCTCGAATTTCTT 
Ifrd2 CACTTTGTTGAGGGTGGTGA AGAGCACTTCCAGTCCGAAG 
Smpdl3b GGATGGGGAGATGGTGTATG GAAGCTGTCGGTATGGTGGT 
Rplp0 TTCATTGTGGGAGCAGAC CAGCAGTTTCTCCAGAGC 
E-cadherin CACCTGGAGAGAGGCCATGT TGGGAAACATGAGCAGCTCT 
ZO-3 ACCCTATGGCCTGGGCTTC CCCGGGTACAACGTGTCC 
N-cadherin ATGTGCCGGATAGCGGGAGC TACACCGTGCCGTCCTCGTC 
Vimentin CTTGAACGGAAAGTGGAATCCT GTCAGGCTTGGAAACGTCC 
DNA 
c-myc fl/fl TCTAGACTTGCTTCCCTTGCTGT TTCCTGTTGGTGAAGTTCACGT 
c-myc -/- AAATAGTGATCGTAGTAAAATTTAGCCTG ACCGTTCTCCTTAGCTCTCACG 
Nucleolin GGCGTGGTGACTCCACGT CGAAATCACCTCTTAAAGCAGCA 
 
Table 2: Oligonucleotide sequences used in real-time PCR analysis for mRNA and genomic DNA 
evaluation. 
 
Primary antibodies 
Antigen Technique Info Dilution 
CD24-PE FACS - 1:200 
Lin+ (CD45-, CD31-, 
Ter119- biotin) FACS - 1:300 (each) 
CD49f-APC FACS - 1:20 
Epcam-PeCy7 FACS - 1:600 
Myc (Y69) Western Blot Rabbit monoclonal 1:10000 
Vinculin (V9264) Western Blot Mouse monoclonal 1:10000 
Myc (Y69) IHC Rabbit monoclonal 1:100 
Ki67 (M7249) IHC Rat monoclonal 1:500 
 
 Secondary antibodies  
Antigen Technique Dilution 
Streptavidin-Alexa488 FACS 1:100 
Anti-Rabbit IgG Western Blot 1:5000 
Anti-Mouse IgG Western Blot 1:10000 
HRP-rabbit IHC 1:100 
HRP-rat IHC 1:100 
 
Table 3: List of primary and secondary antibodies used.  
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3. Results 
 
3.1 Immortalized mammary epithelial cell lines from c-mycfl/fl and 
R26-MycERT2 mice 
In order to study the transcriptional role of Myc in mammary epithelial cells, we 
isolated primary epithelial cells from the mammary gland of c-mycfl/fl (Trumpp et 
al., 2001) and R26-MycERT2 (Murphy et al., 2008) mice, allowing conditional 
deletion and activation of Myc, respectively. In particular, c-mycfl/fl cells have LoxP 
sites into the 3’ untranslated region and Intron 1 of the c-myc gene, leading to 
deletion of the gene upon exposure to Cre recombinase. Here, we used a 
membrane permeable TAT-Cre fusion protein (S. K. Joshi, Hashimoto, & Koni, 
2002) to introduce Cre in the cells. Instead the R26-MycERT2 cells express the 
MycER transgene under the ubiquitous Rosa26 locus; they are suitable for Myc 
activation, upon OHT treatment, since the constitutively expressed MycER 
chimeric protein is inactive in the cytoplasm, until OHT is added to the culture and 
allows its translocation to the nucleus. 
Epithelial cells were isolated from both thoracic and inguinal mouse mammary 
glands by mechanical and chemical digestion. The epithelial nature of the resulting 
cell cultures was assessed three days after isolation by FACS analysis: cells were 
positive for the epithelial surface marker CD24 (Figure 11) and negative for 
markers of endothelial, hematopoietic cells or fibroblasts (CD45, CD31, Ter119) 
(Figure 12). 
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Figure 11: CD24 expression (epithelial marker) by FACS analysis. Histogram representing the percentage 
of cells positive for CD24 for R26MycERT2 (on the left) and c-mycfl/fl (on the right) cells respectively, after three 
days of culture. The primary mammary epithelial cells isolated (red) are compared to fibroblasts as negative 
control (black). 
 
 
Figure 12: Lineage markers expression (CD45, CD31, Ter119) by FACS analysis. Histogram representing 
the percentage of cells positive for Lineage markers for R26-MycERT2 (on the left) and c-mycfl/fl (on the right) 
cells respectively, after three days of culture. The primary mammary epithelial cells isolated (blue) are 
compared to not stained cells as negative control (black). 
 
The primary cells cultures, confirmed epithelial by FACS analysis, spontaneously 
underwent an apparent Epithelial to Mesenchymal Transition (EMT) after one 
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passage in conditions of adhesion, with a marked fibroblastoid appearance (Figure 
13A). Hence, we thought to obtain a more stable system through cell 
immortalization by dual p53 and Rb knock-down, as previously described 
(Elenbaas et al., 2001; Karantza Wadsworth & White, 2008). We thus infected 
freshly isolated MMECs with viral vectors expressing shRNAs against the two 
proteins. Over a period of 4-6 weeks, both non-infected and single-infected 
epithelial cells died, whereas double-infected MMECs started growing and became 
immortalized. As expected, the immortalized clones grew in clusters and showed a 
cuboidal shape that was maintained over passages (Figure 13B).  
 
Figure 13: Morphology of the primary and immortalized mammary epithelial cells. (A) A representative 
image of the MMECs after one passage in culture in adhesion conditions. They showed flat, mesenchymal-
like shape. (B) The same cells after immortalization by p53 and Rb knockdown showed an epithelial shape. 
 
Several single cell clones from each immortalized bulk population were picked and 
expanded. The mRNA expression of epithelial (E-cadherin, ZO3) and 
mesenchymal markers (Vimentin, N-cadherin) was then analysed by RT-qPCR, 
both in the bulk population and in each clone at the same passage (Figure 14). On 
the basis of their morphological aspect and molecular profile, the two clones with 
the strongest epithelial phenotype of each population were selected for further 
analysis (clones C3 and E4 for R26-MycERT2 cells, clones A2 and A4 for c-mycfl/fl 
derived cells). 
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Figure 14: Gene expression analysis of epithelial clones by RT-qPCR analysis. mRNAs level of epithelial 
(E-cadherin, ZO3) and mesechymal (Vimentin, N-cadherin) genes in different clones picked from the 
immortalized bulk populations of mammary epithelial cells. In the upper panel are showed data from R26-
MycERT2 MMECs, in the lower panel from c-mycfl/fl MMECs, respectively. All data were normalized respect to 
the Rplp0 housekeeper gene and the reference bulk population. The bar plots represent the average values, 
standard deviations are calculated between three independent measurements. 
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3.2 Regulation of Myc levels in immortalized MMECs 
Once we obtained stable epithelial cell clones of the desired genetic background, 
we set up the best conditions for Myc super-activation or deletion. 
3.2.1 R26-MycERT2 MMECs 
Epithelial clones originated from R26-MycERT2 mice were stimulated by standard 
concentration of OHT (200 nM) known to induce translocation of the MycER 
chimera in the nucleus in other cellular systems (Littlewood, Hancock, Danielian, 
Parker, & Evan, 1995). We confirmed the activation of MycER transcriptional 
activity by RT-qPCR analysis of known Myc target genes (Smpdl3b and Ifdr2) 
(Marinkovic et al., 2004) in a 48 hours time course experiment (Figure 15). The 
best time point (24 hours) of transcriptional response to MycER was selected for 
the following experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Time course of MycER transcriptional activation by OHT stimulation of R26-MycERT2 
MMECs. The mRNAs level of known Myc targets genes (Smpdl3b and Ifdr2) was monitored in MycER 
MMECs stimulated by 200 nM OHT for 1, 2, 4, 8, 24 and 48 hours. The data are normalized respect to the 
Rplp0 housekeeper gene and not treated samples. The line charts displays the average values and standard 
deviation between two independent clones (C3 and E4), each one done in technical duplicate, at different time 
points. 
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We compared the expression of the same genes in MMECs without MycER 
relative to MMECs R26-MycER (not treated by OHT), to confirm the absence of 
leakiness in the system (Figure 16). 
 
 
 
 
 
 
 
 
 
 
Figure 16: Control of the absence of leakiness of R26-MycERT2 MMECs. The mRNA levels of known Myc 
targets genes (Smpdl3b and Ifdr2) was monitored in MMECs without R26-MycER compared to MMECs with 
R26MycER, not treated by OHT. The data are normalized respect to the Rplp0 housekeeper gene. The bars 
plot displays the average values and standard deviation between two measurements on the bulk population. 
 
We also verified the expression of the exogenous human MycER protein by 
western blot (Figure 17): 24h of OHT treatment increased the level of the chimeric 
protein (possibly by increasing its stability) and led to a reduction in the levels of 
endogenous Myc (possibly by the transcriptional repressive activity exerted by the 
exogenous protein (Facchini, Chen, Marhin, Lear, & Penn, 1997; L. J. Penn et al., 
1990). 
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Figure 17: Myc super-activation in R26-MycERT2 mammary epithelial clones stimulated by OHT for 24 
hours. Myc protein detected by western blot analysis using Myc Y69 antibody (Abcam) in not treated (+EtOH, 
vehicle) and treated samples (+ 200 nM OHT) for 24 hours. The upper band (about 97 kDa) represents the 
exogenous human MycER protein; the lower band (52 kDa), instead, is the endogenous murine Myc protein. 
Vinculin protein (130 kDa) is used as reference for protein level normalization. 
3.2.2 c-mycfl/fl MMECs 
In c-mycfl/fl MMECs, deletion of the c-myc allele was achieved treating the cells 
with the recombinant TAT-Cre recombinase (100 µg/ml) for 2 hours. As judged by 
either genomic DNA (gDNA) or mRNA analysis 24 hours after treatment, an 
effective c-myc knockout (above 80-90%) was reached in these conditions (Figure 
18).  
 
Figure 18: gDNA and mRNA levels of c-myc in c-mycfl/fl MMECs treated with TAT-Cre recombinase. 
Myc levels in c-mycfl/fl epithelial clones treated or not with TAT-Cre (100 µg/ml, 2 hours) and analysed after 24 
hours. The bars plot on the left shows genomic DNA copy number respect to the Nucleolin amplicon and not 
treated cells. Instead, the bars plot on the right shows the mRNA levels relative to Rplp0 housekeeper gene 
and not treated cells. The average and standard deviation between two independent clones (A2 and A4), each 
one done in technical duplicate is reported. 
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We confirmed the complete ablation of the endogenous c-Myc in these conditions 
also at protein level (Figure 19). 
 
 
 
 
 
 
Figure 19: Myc protein ablation in c-mycfl/fl mammary epithelial clones treated with TAT-Cre. Myc 
protein detected by western blot analysis using Myc Y69 antibody (Abcam) in not treated (-TAT-Cre) and 
treated samples (+ 100 µg/ml TAT-Cre, 2 hours). As expected, there is the complete disappearance of Myc 
protein (52kDa) 24 hours after the TAT-Cre treatment. Vinculin protein (130kDa) is used as reference for 
protein level normalization. 
 
3.3 Myc negatively controls the expression of genes involved in 
extracellular matrix interaction, cell adhesion and epithelial 
morphogenesis regulation 
c-mycfl/fl and R26-MycERT2 MMECs treated with TAT-Cre or OHT to induce Myc 
deletion or activation were subjected to mRNA profiling by RNA-seq: for each 
condition, two different cell clones (biological replicates) were used and for each 
clone two technical replicates were prepared, producing a total of 4 replicates per 
sample. Differentially Expressed Genes (DEGs) between treated samples (+TAT-
Cre or +OHT) and control (-TAT-Cre or -OHT) were identified using the 
Bioconductor package DESeq2 considering genes whose q-value relative to the 
control sample was lower than 0.01 (FDR ≤ 1%) and whose eRPKM expression 
value was ≥ 1 in at least one condition (see Material and Methods). We thus 
identified 4787 DEGs (2340 up- and 2447 down- regulated) upon MycER 
activation (akin to Myc Overexpression, henceforth MycOE) and 4687 DEGs (2262 
up- and 2425 down- regulated) upon Myc deletion (Myc Knock-Out, henceforth 
MycKO) relative to the corresponding control sample. 
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In order to identify the core Myc transcriptional program in MMECs, we searched 
for genes regulated in opposite way by Myc up-regulation and deletion. For this 
purpose, we first identified the genes expressed in both systems (eRPKM ≥ 1 in 
both systems). Starting from 12568 genes expressed in MycOE and 12514 genes 
expressed in MycKO, we found 11930 genes commonly expressed. We plotted 
their changes in expression relative to control (as Log2 fold change) upon Myc 
modulation in the two conditions (Figure 20). 
 
Figure 20: Transcriptional changes of common expressed genes in Myc overexpressing and c-myc 
deleted cells. The scatter plot shows all the 11930 common expressed genes between Myc overexpressing 
(MycOE) and c-myc deleted (MycKO) cells. Each dot is a gene and it is positioned on the basis of its changes 
in expression in MycOE (y axes) and MycKO (x axes) samples relative to the Control (expressed as Log2 fold 
change). The two datasets show moderate anti-correlation, calculated by Pearson coefficient ρXY= -0.48, p-
value < 2.2e-16. 
 
As expected, we observed a moderate anti-correlation in the transcriptional 
responses to Myc activation and deletion (Pearson coefficient = -0.48). We then 
selected those genes that were regulated in a statistically significant manner in 
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both systems (q-value ≤ 0.01; FDR ≤ 1%, 2409 genes), thus the anti-correlation 
between the two systems improved (Pearson coefficient = -0.67). Among the 
significant genes, we selected those that were regulated in an opposite manner in 
the two systems. In this way we identified 1180 Myc-induced genes (up-regulated 
in MycOE and down-regulated in MycKO) and 1065 Myc-repressed genes (down-
regulated in MycOE and up-regulated in MycKO) (Figure 21). 
	  
 
Figure 21: The core of Myc transcriptional program in MMECs. The scatter plot shows all the 2409 genes 
regulated in a statistically significant manner (q-value ≤ 0.01; FDR ≤ 1%) both in MycER activation (MycOE) 
and c-myc deleted (MycKO) cells. Each dot represents a gene and it is positioned on the basis of its changes 
in expression in MycKO (x axes) and MycOE (y axes) samples relative to the Control (expressed as Log2 fold 
change). Genes regulated oppositely by Myc modulation in the two systems represented the core of Myc 
transcriptional program. In particular in green are highlighted Myc-repressed genes, (down-regulated upon 
MycER activation and up-regulated upon c-myc deletion), instead in red are highlighted the Myc-induced 
genes (up-regulated upon MycER activation and down-regulated upon c-myc deletion). The black dots are 
those genes that were not coherently regulated in the two cellular models, which as expected were very few 
genes. Considering only the significant genes, the anti-correlation between the two datasets, calculated by 
Pearson coefficient, increases ρXY= -0.67, p-value < 2.2e-16. 
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Gene Ontology analysis of the 1180 Myc-induced genes, identified the main 
biological function promoted by Myc in MMECs as proliferation, metabolism, 
ribosomal biogenesis, RNA processing and modification (mRNA, rRNA, ncRNA), 
mitochondrial organization, chromatin modification, all categories that were as also 
previously found in several other cell types (Dang, 2014; Eilers & Eisenman, 2008; 
Kress et al., 2015) (Table 4). 
	  
GO ID Term p-value 
GO:0034660 ncRNA metabolic process 1.96E-54 
GO:0042254 ribosome biogenesis 7.04E-47 
GO:0044429 mitochondrial part 1.55E-14 
GO:0000166 nucleotide binding 3.55E-14 
GO:0006259 DNA metabolic process 1.84E-13 
GO:0004386 helicase activity 6.99E-12 
GO:0007049 cell cycle 1.17E-11 
GO:0006397 mRNA processing 4.60E-11 
GO:0009451 RNA modification 3.39E-10 
GO:0016568 chromatin modification 3.59E-07 
 
Table 4: The top ten Gene Ontology categories of Myc–induced genes in MMECs in adhesion. The 
individuated 1180 Myc-induced genes in MMECs in adhesion have been submitted to Gene Ontology analysis 
(http://david.abcc.ncifcrf.gov). The top ten scoring GO categories are listed with the corresponding p-value.  
 
The same analysis has been performed for the 1065 Myc-repressed genes. This 
list of genes was enriched for categories such as lysosome and vesicle-mediated 
transport, angiogenesis, cell death, extracellular matrix and cell adhesion 
regulation, epithelial development and morphogenesis (Table 5). 
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GO ID Term p-value 
GO:0005764 lysosome 9.05E-10 
GO:0043169 cation binding 2.91E-05 
GO:0001568 blood vessel development 4.76E-05 
GO:0030695 GTPase regulator activity 6.47E-05 
GO:0031012 extracellular matrix 1.67E-04 
GO:0007155 cell adhesion 1.00E-03 
GO:0016192 vesicle-mediated transport 1.00E-03 
GO:0008219 cell death 2.00E-03 
GO:006042 epithelium development 1.00E-02 
GO:0002009 morphogenesis of an epithelium 1.00E-02 
 
Table 5: The top ten Gene Ontology categories of Myc–repressed genes in MMECs in adhesion. The 
individuated 1065 Myc-repressed genes in MMECs in adhesion have been submitted to Gene Ontology 
analysis (http://david.abcc.ncifcrf.gov). The top ten scoring GO categories are listed with the corresponding p-
value. 
 
Among the biological functions repressed by Myc in epithelial cells, we focused 
our attention on extracellular matrix interactions, cell adhesion and differentiation. 
Previous observations highlighted the pivotal role of Myc in mammary epithelial 
cells in controlling stem cells and progenitors function (Moumen et al., 2012; Pasi 
et al., 2011) in part by promoting the acquisition of more mesenchymal and 
aggressive features associated to EMT and cancer stem cell generation (Bin Cho 
et al., 2010; Jackstadt et al., 2013; M. Liu et al., 2009; A. P. Smith et al., 2008; 
Trimboli et al., 2008). We hypothesized that these functions of Myc could be 
mediated, at least partially, by its repressive activity (Gebhardt, 2006; Kerosuo et 
al., 2008). 
 
3.4 A role for Miz1 binding in Myc-induced self-renewal of 
mammary epithelial stem cells 
Among the co-factors reported to cooperate with Myc in transcriptional repression, 
Miz1 appears to be the most relevant (Peukert et al., 1997) and may be required 
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for a large fraction (25-40%) of Myc-down-regulated genes (Walz et al., 2014). 
Normally, Miz1 acts as transcriptional activator in association with the histone 
acetyltransferase p300 and nucleophosmin. The co-operation with Myc or other 
transcription factors, turns Miz1 in a repressive factor (Steffi Herold et al., 2002; 
Staller et al., 2001; Wanzel et al., 2008). The repressive role of Myc/Max/Miz1 
trimers is well documented on survival/apoptotic genes and on cell adhesion and 
differentiation/self-renewal related genes (Gebhardt, 2006; Kerosuo et al., 2008). 
To further study the transcriptional repressive role of Myc, and in particular its 
interaction with Miz1 in self-renewal of mammary epithelial stem cells, we took 
advantage of a Myc mutant unable to bind Miz1 (MycV394D, henceforth Myc VD) 
(Steffi Herold et al., 2002). This mutation in the Myc protein does not affect its 
association with Max, allowing the identification of the Miz1-dependent functions of 
Myc (Walz et al., 2014). 
3.4.1 Evaluation of self-renewal and growth rate  
Primary mammary epithelial cells were isolated from Tet-On mouse models able to 
ubiquitously overexpress MYC WT or VD upon Doxycycline treatment (TET-MYC-
WT/R26rtTA and TET-MYC-VD/R26rtTA mice). The cells were grown in non-
adherent conditions in a mammosphere assay (Dontu et al., 2003), to measure in 
vitro their self-renewal ability. Indeed, the mammospheres are enriched in early 
progenitor/stem cells able to propagate in culture and to differentiate along all 
three mammary epithelial lineages. On the contrary the late progenitor/mature 
cells, also present within the mammospheres, when seeded in the following 
passages stop growing or undergo to cell death for anoikis, because of their 
inability to regenerate spheres in non-adherent conditions (Figure 22). 
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Figure 22: Schematic representation of mammospheres assay. Mammary epithelial cells derived from Ctr 
(TET-MYC/wt), MYC WT (TET-MYC-WT/R26rtTA) and MYC VD (TET-MYC-VD/R26rtTA) mice cultured in 
suspension in undifferentiated conditions are able to form mammospheres. This assay is a surrogate of stem 
cells propagation in vitro, since only early progenitors/stem cells are able to propagate and regenerate 
spheres in serial passages. On the contrary late progenitors/mature cells differentiate and stop growing or 
undergo to cell death for anoikis (modified from (Dontu et al., 2003). 
 
Freshly isolated mammary epithelial cells of the selected genotypes were plated in 
non-adherent conditions for two weeks (M0-M1) in order to remove all the 
contaminant cells (above all fibroblast, endothelial and hematopoietic cells). After 
that, a single-cell suspension was seeded and the resulting mammospheres were 
serially passaged (M2, M3, M4, M5) once a week in the presence of Doxycycline 
(2 µg/ml, administered twice a week) (Figure 23). At each passage, we evaluated 
the Sphere Forming Efficiency (SFE), Growth Rate (GR) and the area of the newly 
formed mammospheres in order to characterize the stem potential of cells over-
expressing both forms of MYC, relative to control wild type cells.  
	  
 
Figure 23: Schematic representation of the experimental design. Murine mammary epithelial cells were 
selected in culture for two weeks (M0-M1). Hence, they were serially passaged (M2-M5) in the presence of 
Doxycycline (grey arrow), each passage lasted one week. During these passages Sphere Forming Efficiency 
(SFE), Growth Rate (GR) and spheres size were evaluated. 
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First of all we verified the absence of leakiness of the Tet-On system. We 
compared the expression of two Myc-targets (Smpdl3b and Ifdr2) in primary 
MMECs both TET-MYC/R26rtTA without Doxycycline and TET-MYC/wt upon 
induction with Doxycycline (for 48h) (Figure 24). As expected there are no effect 
due to Doxycycline, neither any leakiness of the Tet-On system. 
	  
 
 
 
 
 
 
 
 
Figure 24: Control of the absence of leakiness of the TET-MYC MMECs. The mRNA levels of known Myc 
targets genes (Smpdl3b and Ifdr2) were monitored in TET-MYC/R26rtTA MMECs (-Doxy) compared to TET-
MYC/wt MMECs (+Doxy for 48 hours). The data are normalized respect to the Rplp0 housekeeper gene. The 
bars plot displays the average values plus standard deviation between two independent measurements. 
 
Then, we checked the over-expression of c-MYC WT and VD transgenes both at 
mRNA and protein levels. In particular the mRNA was analysed immediately after 
one week of culture of the mammary epithelial cells (M0, before starting the 
treatment with Doxycycline) and after one (M1), three (M3) and five (M5) weeks of 
c-MYC induction by Doxycycline. Starting from the same levels of endogenous c-
myc (mouse), the induction of the exogenous c-MYC (human) is comparable 
between MYC WT and VD in the first passage (M1) and slightly higher in MYC VD 
samples respect to MYC WT at M3 and M5. As expected, the induction of c-MYC 
was also able to repress the endogenous c-myc and to induce Myc targets such 
as Ifdr2 and Smpdl3b (Figure 25). 
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Figure 25: Gene expression analysis in mammospheres overexpressing MYC WT and VD. mRNAs 
extracted from primary mammary epithelial cells (Ctr, MYC WT and MYC VD) grown as mammospheres 
before (M0) and after Doxycycline induction for the entire duration of the experiment (M1, M3, M5). The bars 
plots show the mRNA levels of the endogenous c-myc (mouse), exogenous Doxycycline-induced c-MYC 
(human) and Myc targets (Ifdr2 and Smpdl3b) relative to Rplp0 housekeeper gene. Standard deviations are 
measured considering three replicates of the experiment. 
 
In the end, we verified the expression of the c-MYC WT and VD transgenes at the 
protein level after one (M1), three (M3) and five (M5) weeks of c-MYC induction by 
Doxycycline and found that Myc quantity was comparable between the WT and 
the mutant VD protein (Figure 26). 
 
 
 
 
 
 
 
Figure 26: Myc protein overexpression in mammospheres. Myc protein detected by western blot analysis 
using Myc Y69 antibody (Abcam) in primary mammospheres (Ctr, MYC WT and MYC VD) treated by 2 µg/ml 
Doxycycline for one (M1), three (M3) and five (M5) weeks. c-Myc protein is represented by two bands (52 
kDa, 40 kDa). Vinculin protein (130kDa) is used as reference for protein level normalization. 
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Since in non-adherent conditions only the stem cells were able to survive and give 
rise to small aggregates of proliferating cells, called mammospheres, the number 
of growing spheres was an indirect measurement of the stem cells contained in 
the population. We measured the Sphere Forming Efficiency (SFE) as percentage 
of sphere-forming units for a certain number of cell seeded. In general, 
mammospheres originated from MYC-overexpressing cells were different relative 
to the control, showing increases in both number and size (Figure 27). Compared 
with MYC WT, this effect was reproducibly lower in MYC VD overexpressing cells. 
	  
 
Figure 27: Primary mammospheres originated from MYC overexpressing (WT and VD) and control 
cells. Representative images of mammospheres originated from control (Ctr) and MYC (WT and VD) 
overexpressing cells at M2 and M3 passages of the assay. The scale bar of reference is 2000 µm. 
 
In particular, MYC-overexpressing cells showed increases in SFE of four to ten 
folds relative to control cells (Figure 28). This difference was higher in the first part 
of the experiment (M2-M3), whereas it decreased in the second part (M4-M5). 
MYC VD showed the same behaviour of MYC WT, but with a milder increase of 
the SFE (five to two folds). 
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Figure 28: Sphere forming efficiency (SFE) of MYC overexpressing (WT and VD) and control 
mammospheres. The Sphere Forming Efficiency (SFE) for Ctr (blue), MYC WT (red) and MYC VD (green) 
overexpressing cells over the passages (M2-M5). The lines chart display the average values calculated 
between three independent experiments (two technical replicates for each) ± standard deviation. t-test 
statistical analysis between Ctr or MYC VD samples respect to MYC WT showed respectively: NS= Not 
Significant, ∗ = p-value ≤ 0.05, ∗∗ = p-value ≤ 0.01 significant difference, at each passage. 
 
In addition, we measured the Growth Rate (GR) as number of cells counted after 
mammospheres disgregation for number of cells seeded to assess the proliferative 
potential of the mammospheres. We observed that MYC WT over-expression 
significantly enhanced the growth rate (three to five fold) of the mammospheres 
(Figure 29). These differences were observed at all passages, but in particular at 
M2 and M3. As above, MYC VD had a milder phenotype but in this case the 
differences between MYC WT and VD were not statistically different. 
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Figure 29: Growth rate (GR) of MYC overexpressing (WT and VD) and control mammospheres. The 
Growth Rate (GR) has been measured for Ctr (blue), MYC WT (red) and MYC VD (green) overexpressing 
cells as the number of cells originate from disgregation of newly formed mammospheres divided by the 
number of seeded single-cells over the passages (M2-M5). The lines chart display the average values 
calculated between three independent experiments (two technical replicates for each) ± standard deviation. t-
test statistical analysis between Ctr or MYC VD samples respect to MYC WT showed respectively: NS= Not 
Significant, ∗ = p-value ≤ 0.05, ∗∗ = p-value ≤ 0.01 significant difference, at each passage. 
 
Lastly, we compared the sphere size in the three experimental groups and we 
found that MYC WT over-expression increased the area of the mammospheres 
significantly respect to the control cells. These differences were observed at all 
passages, but in particular at M2. Again MYC VD had a milder phenotype that was 
significantly different from the WT at M2 and M3 passages (Figure 30). 
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Figure 30: Size (Area) of MYC overexpressing (WT and VD) and control mammospheres. The sphere 
size has been measured for Ctr (blue), MYC WT (red) and MYC VD (green) overexpressing cells. The area of 
the spheres is calculated in pixels considering spheres with diameter more than 80 µm (≥600 pixels) and 
circularity >0.2 (this parameter considers the roundness of the spheres to exclude mere cell aggregates), 
using ImageJ software. The bars plot show the average values calculated between three independent 
experiments (two technical replicates for each) ± standard deviation. t-test statistical analysis between Ctr or 
MYC VD samples respect to MYC WT showed respectively: NS= Not Significant, ∗ = p-value ≤ 0.05, ∗∗ = p-
value ≤ 0.01 significant difference, at each passage. 
 
In conclusion MYC overexpressing mammary epithelial cells showed an increased 
sphere forming efficiency in vitro in mammosphere assays, suggesting enhanced 
self-renewal ability. The MYC VD mutant was less effective suggesting that the 
interaction between Myc and Miz1 could be partially responsible for the observed 
phenotype.  
3.4.2 Evaluation of proliferation and apoptosis 
Since Myc is a well-known regulator of cell cycle progression and proliferation 
(Amati et al., 1998; Oster et al., 2002), and given the prominent role of Myc/Miz1 
interaction in the regulation of apoptosis (Patel & McMahon, 2006; Seoane et al., 
2002; Staller et al., 2001), we verified if the observed differences between MYC 
WT and VD were attributable to an alteration in these functions rather than in self-
M2 M3 M4 M5
0
500
1000
1500
2000
Passages
A
re
a 
(p
ix
el
s)
Ctr
MYC WT
MYC VD
**
**
*
*
NS
*
*
NS
 77 
renewal ability. To distinguish between these two hypotheses, we evaluated cell 
cycle distribution and cell death in Ctr or MYC (WT or VD) over-expressing 
mammospheres 48 and 96 hours after seeding between M2 and M3 passages. 
As expected, Myc overexpressing cells had a higher proliferation rate compared to 
control, with more cells in S-phase, as shown by increases EdU staining, both at 
48 and 96h (Figure 31). MYC VD overexpression was slightly less effective than 
MYC WT at 48h, while it had a comparable effect in proliferation at 96h, while it 
was significant different, as MYC WT, relative to the control (at bot time points). 
	  
 
Figure 31: Cell cycle distribution of MYC overexpressing (WT and VD) and control cells. The cell cycle 
distribution has been evaluated by EdU/PI staining in Control and Myc overexpressing (WT and VD) 
mammospheres, at 48 and 96 hours after seeding (passage M2-M3). Bar plots representing the average 
values of two independent experiments ± standard deviation. t-test statistical analysis between Ctr or MYC VD 
samples respect to MYC WT showed respectively: NS= Not Significant, ∗ = p-value ≤ 0.05, ∗∗ = p-value ≤ 
0.01 significant difference. 
 
We also evaluated the apoptotic rate in the same conditions (Figure 32). Although 
Myc is a known inducer of apoptosis (Patel & McMahon, 2006), it has been 
demonstrated that this occurs only when its levels raise above a certain threshold 
(Murphy et al., 2008). In our conditions, the level of MYC overexpression obtained 
seemed to be rather protective versus apoptosis, since control cells showed the 
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highest cell death. This paradoxical observation may be explained by the fact that 
in non-adherent conditions cells undergo massive cell death due to anoikis and 
Myc overexpression could increase the number of cells resistant to anoikis (Paoli, 
Giannoni, & Chiarugi, 2013). There were minor, not statistically significant, 
differences between MYC WT and MYC VD. 
	  
 
Figure 32: Cell death of MYC overexpressing (WT and VD) and control cells. Cell death has been 
evaluated by AnnexinV/PI staining in Control and MYC overexpressing (WT and VD) samples, at 48 and 96 
hours after seeding (passage M2-M3). AnnexinV marks the cells in early apoptosis; instead the double 
staining AnnexinV/PI marks the cells in late apoptosis/necrosis. Myc overexpressing samples displayed 
significantly less cell death respect to the Control, at both time points. There was no significant difference 
between MYC WT and VD cells. Bar plots representing the average values of two independent experiments ± 
standard deviation. t-test statistical analysis between Ctr or MYC VD samples respect to MYC WT showed 
respectively: NS= Not Significant, ∗ = p-value ≤ 0.05, ∗∗ = p-value ≤ 0.01 significant difference. 
 
In conclusion Myc overexpression increases the proliferation rate and decreases 
apoptosis of mammary epithelial cells grown as mammospheres. This appears to 
be largely independent from Miz1, since MYC WT and VD have very similar 
effects. Thus, proliferation and apoptosis alone could not explain the differences in 
SFE between MYC WT and VD, suggesting that the defect of MYC VD relates to 
its lower ability to promote self-renewal, relative to MYC WT.  
3.4.3 In vivo mammary reconstitution assays 
Since we wanted to prove that Myc has a Miz1-dependent function in promoting 
self-renewal, we decided to functionally measure stem cell frequencies in MYC 
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WT and VD overexpressing populations in vivo. Thus, we performed mammary 
reconstitution assays (Illa-Bochaca et al., 2010). 
We obtained mammospheres from Ctr, TET-MYC-WT and TET-MYC-VD R26rtTA 
mice, and collected the cells 48 hours after seeding as single-cell suspensions, 
between the M2 and M3 passages. We then transplanted them in serial dilutions 
(1000, 500, 100 cells) into the cleared fat pads of 3 weeks old AthymicNude-
Foxn1nu host mice. Transplanted mammary fat pads were examined for gland 
reconstitution 12 weeks post-injection by whole mount staining. The presence of 
branched ductal trees with lobules and/or terminal end buds was considered as 
positive reconstitution. A representative image of mammary gland reconstitution 
with MYC WT cells is shown in Figure 33. 
 
Figure 33: Whole-mount analysis of the transplanted mammary glands. (A) A representative image of the 
transplanted mammary glands in which is occurred reconstitution. The exogenous reconstitution is 
distinguishable from the endogenous one because of its typical central growth in the gland. (B) A 
magnification (2X) of the image clearly shows the morphology of the branched ductal trees. 
 
The frequency of Mammary Stem Cells (MaSCs) in the transplanted cell 
population was calculated through the serial dilution transplantation using the 
Extreme Limiting Dilution Analysis Program (http://bioinf.wehi.edu.au/ 
software/elda/index.html) (Wenjun Guo et al., 2012; Hu & Smyth, 2009) and 
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reported in Table 6. The calculated SCs frequencies were significantly higher in 
MYC WT than in Ctr and MYC VD cells, while there are no significant differences 
between Ctr and MYC VD cells. 
	  
Group n. injected cells 
Mammary glands 
outgrowths/ 
injection 
Estimate 
stem cells frequency 
(upper and lower limits) 
p-value 
Ctr 
1000 0/4 
1:8348 
(1:1161-1:59998) 
0.0215 500 1/8 
100 0/6 
MYC WT 
1000 1/6 
1:1193 
(1:557-1:2553) - 500 2/8 
100 5/9 
MYC VD 
1000 0/2 
1:4816 
(1:1550-1:14963) 0.0274 500 1/4 
100 2/10 
 
Table 6: Frequency of stem cells in different mammary cells population. Cell suspensions from 
mammospheres were injected in the mammary glands of 3 weeks old Athymic Nude-Foxn1nu host mice. 
Results are shown as number of outgrowths per number of injections, per each concentration of cells injected. 
SCs frequencies (estimates and upper/lower limits) were calculated by limiting dilution analysis. The statistical 
significance of the difference in SCs frequencies (p-value) between Ctr or MYC VD and MYC WT cells is 
calculated by t-test.  
 
3.5 MYC WT and VD overexpression and tumorigenesis 
To test the tumorigenic potential of MYC WT and VD overexpression in mice, we 
crossed MMTVrtTA mice and TET-MYC WT or VD mice. In this way we obtained 
an in vivo breast-specific conditional up-regulation of either MYC WT or VD. The 
induction of MYC, both WT and VD, and proliferation were monitored in 
immunohistochemistry by staining with anti Myc (Y69) and Ki67 (M7249) 
antibodies respectively after one and three months of induction by Doxycycline 
diet in two mice for each experimental group. As shown in the panels in Figure 34, 
after one month of induction we scored neither a real activation of the MYC 
transgenes, nor an induction of proliferation.  
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Figure 34: Immunohistochemical analysis of TET-MYC (WT and VD) MMTVrtTA and control mice. 
Hematoxylin and Eosin (HE), Ki67, c-Myc (Y69) immunohistochemistry were performed on Ctr and TET-MYC 
(WT and VD) MMTVrtTA mice induced in vivo by Doxycycline food for 30 days. Both from a structural and a 
proliferative point of view, the TET-MYC mice did not show any significant difference respect the control mice. 
The over-expression of the transgenes was too low at this time point. (Scale bar: HE= 200 µm, Ki67 and c-
Myc =50 µm). 
 
We verified also MYC overexpression in vivo after three months of induction by 
Doxycycline in two mice for each experimental group. As shown in the panels in 
Figure 35, at this stage the activation of MYC transgenes was much improved. We 
were able to notice a more homogenous induction of MYC (WT and VD) in all the 
cells of the same ductal structure and in all the ducts of the mammary gland. 
Moreover the transgenes seemed to be expressed prevalently in the luminal, more 
than in the basal compartment of the ducts. Also the proliferation, evaluated by 
Ki67 staining, was higher respect to the mammary gland of the control. 
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Figure 35: Immunohistochemical analysis of TET-MYC (WT and VD) MMTVrtTA and control mice. 
Hematoxylin and Eosin (HE), Ki67, c-Myc (Y69) immunohistochemistry were performed on Ctr and TET-MYC 
(WT and VD) MMTVrtTA mice induced in vivo by Doxycycline food for 90 days. Both Myc and Ki67 staining 
were significantly increased in TET-MYC mice respect the control mice. (Scale bar: HE= 400 µm, Ki67 and c-
Myc =100 µm). 
 
In order to verify if there was any structural change due to MYC up-regulation we 
verified the structural development of the mammary glands by whole mount 
staining. We did not score any structural difference between Myc WT and VD, 
neither between control and MYC-overexpressing cells (Figure 36). 
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Figure 36: Whole mounts of mammary glands of TET-MYC (WT and VD) MMTVrtTA and control mice. 
The whole structure of the mammary gland was stained, in order to verify any structural change in Ctr and 
TET-MYC (WT and VD) MMTVrtTA mice induced in vivo by Doxycycline food for 30 or 90 days. (Scale bar 
2mm). 
 
Since the expected latency for the onset of these tumors is about 22 weeks, after 
one year without tumor development, we decided to sacrifice the animals and 
analyse by FACS whether there was any alteration in the distribution of 
subpopulations (basal and luminal) of the epithelial compartments upon MYC 
overexpression. As shown in Figure 37, we were not able to individuate significant 
differences in the expression of basal vs. luminal surface markers in MYC 
overexpressing cells compared to control. 
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Figure 37: Basal/Luminal cells in TET-MYC (WT and VD) MMTVrtTA and control mice. The ratio between 
Basal (CD49fhigh/Epcamhigh) and Luminal (CD49flow/Epcamhigh) cells subpopulation in the epithelial 
compartment (Lin-) was evaluated in Ctr and TET-MYC (WT and VD) MMTVrtTA mice induced in vivo by 
Doxycycline food for one year. Bar plots representing the average values of two independent experiments ± 
standard deviation. t-test statistical analysis between Ctr or MYC VD samples respect to MYC WT showed not 
significant (NS) differences. 
 
The lack of any phenotype of the MMTV-Myc mice, not even the ones reported in 
literature (D'Cruz et al., 2001), and also of a clear indication of transgene 
overexpression and activity, made us to conclude that we need to address the 
tumorigenic potential of MYC WT and VD in mammary epithelial cells with a 
different experimental approach. One possibility that we are currently evaluating 
would be to transplant MYC-overexpressing (WT and VD) and control epithelial 
cells in 6 weeks old AthymicNude-Foxn1nu host mice, after having infected them 
with a viral vector expressing other oncogenes (i.e. Ras) to shorten the latency of 
tumorigenesis. 
 
3.6 Myc/Miz1 interaction is necessary for the regulation of genes 
involved in extracellular matrix interaction, cell adhesion and 
epithelial morphogenesis 
3.6.1 RNA-seq analysis 
In order to find the transcriptional program underlying the observed phenotypes, 
MYC WT and VD overexpressing mammospheres together with control samples 
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(collected at 48 hours after seeding as single-cell suspensions between the M2 
and M3 passages) were subjected to mRNA profiling. Differentially expressed 
genes (DEGs) were identified by RNA-seq analysis using the Bioconductor 
package DESeq2 considering genes whose q-value relative to the control sample 
is lower than 0.01 (FDR ≤ 1%) and whose expression is higher than eRPKM of 1 
(see Material and Methods). We found 3902 up- and 3799 down-regulated genes 
in MYC WT overexpressing cells relative to the control and 2960 up- and 3005 
down- regulated genes in MYC VD respect to the control.  
To map the genes responsible for the differences in SFE in MYC WT relative to 
MYC VD, we first selected the genes expressed at least in one condition (Ctr, 
MYC WT or VD) and plotted those 13919 genes in a scatter plot in witch each 
gene is a dot and it is positioned on the basis of its changes in expression (Log2 
fold change) in MYC WT and MYC VD overexpressing mammospheres relative to 
the control (Figure 38). The majority of the dots were positioned on the diagonal, 
suggesting a good correlation in the gene regulation between the two systems 
(Pearson coefficient ρXY= 0.85). 
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Figure 38: Transcriptional changes in c-MYC WT and c-MYC VD overexpressing primary 
mammospheres. The scatter plot shows all the 13919 expressed genes in c-MYC WT and c-MYC VD 
overexpressing cells. Each dot is a gene and it is positioned on the basis of its changes in expression in c-
MYC WT (x axes) and c-MYC VD (y axes) overexpressing samples relative to the Control (expressed as Log2 
fold change). The two datasets show good correlation, calculated by Pearson coefficient ρXY= 0.85, p-value < 
2.2e-16. 
 
	  
After this, we selected those genes regulated in a statistically significant manner in 
at least one system (q-value ≤ 0.01; FDR ≤ 1%, 8445 genes) and among them 
only the genes differentially regulated in the two systems, having a difference of at 
least 1.5 fold change (|Log2FC WT - Log2FC VD |>0.585). We identified 305 genes 
induced in MYC WT overexpressing samples and less induced/repressed by MYC 
VD overexpression (red/green dots in Figure 39). As expected, the differences 
between MYC WT and VD were even more consistent for the repressed genes, 
since we found 888 genes repressed by MYC WT and less repressed by MYC VD 
(green dots in the scatter plot Figure 39). Indeed, it has been already shown that 
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dampening Myc/Miz1 interaction (by shRNA against Miz1 or tacking advantage of 
the MYC VD mutant) has no effect on Myc activated genes, while it causes de-
repression on part of Myc down-regulated genes (Walz et al., 2014; Wiese et al., 
2015). 
 
Figure 39: Genes differentially regulated between c-MYC WT and c-MYC VD overexpressing primary 
mammospheres. The scatters plot shows all the 8445 genes regulated in a statistically significant manner (q-
value ≤ 0.01; FDR ≤ 1%) in c-MYC WT or in c-MYC VD overexpressing cells respect to control. Each dot is a 
gene and it is positioned on the basis of its changes in expression in c-MYC WT (x axes) and c-MYC VD (y 
axes) samples relative to the control (expressed as Log2 fold change). In particular: in green are highlighted 
the genes repressed by MYC WT and, less repressed/induced by MYC VD (888 genes), in red are highlighted 
genes induced by MYC WT and less induced/repressed by MYC VD (305 genes). The grey dots are those 
genes that are regulated in a similar manner in the two systems (|Log2FC WT - Log2 FC VD|<0.3). 
Considering only the significant genes, the correlation between the two datasets, calculated by Pearson 
coefficient, is good: ρXY= 0.86, pvalue < 2.2e-16. 
 
After defining these functional categories, we performed Gene Ontology analysis 
for each of them. We started from the 888 genes differentially repressed by MYC 
WT and VD. The top scoring GO terms are listed in Table 7. 
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Among the molecular function enriched in these DEGs there are terms related to 
cell adhesion and motility. 
	  
GO ID Term p-value 
GO:000268 positive regulation of immune system process 1.19E-24 
GO:0009611 response to wounding 5.72E-22 
GO:0009986 cell surface 8.03E-17 
GO:0001817 regulation of cytokine production 2.27E-11 
GO:0030695 GTPase regulator activity 5.30E-10 
GO:0042330 taxis 4.51E-09 
GO:0006909 phagocytosis 8.47E-09 
GO:0010941  regulation of cell death 5.10E-07 
GO:0007155 cell adhesion 1.12E-04 
GO:0010648 negative regulation of cell communication 1.18E-04 
 
Table 7: The top ten Gene Ontology categories of differentially repressed genes between MYC WT and 
VD. The individuated 888 genes repressed by MYC WT and less repressed/induced by MYC VD were 
submitted to Gene Ontology analysis (http://david.abcc.ncifcrf.gov). The top ten scoring GO categories are 
listed with the corresponding p-value. 
 
Similar GO categories were found enriched also in the genes similarly repressed 
between MYC WT and VD (Table 8). 
	  
GO ID Term p-value 
GO:0016327 apicolateral plasma membrane 7.14E-20 
GO:0007155 cell adhesion 2.14E-07 
GO:0060429 epithelium development 9.19E-07 
GO:0030855 epithelial cell differentiation 5.18E-06 
GO:0045860 positive regulation of protein kinase activity 1.08E-04 
GO:0048598 embryonic morphogenesis 2.90E-04 
GO:0030030 cell projection organization 3.36E-04 
GO:0060284 regulation of cell development 3.79E-04 
GO:0014033 neural crest cell differentiation 4.36E-04 
GO:0005604 basement membrane 2.30E-03 
 
Table 8: The top ten Gene Ontology categories of negatively regulated genes by both MYC WT and VD. 
The individuated 640 genes repressed both by MYC WT and MYC VD were submitted to Gene Ontology 
analysis (http://david.abcc.ncifcrf.gov). The top ten scoring GO categories are listed with the corresponding p-
value. 
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Thus, we found that Myc/Miz1 complex contribute to part of the negative regulation 
due to Myc overexpression of genes involved in extracellular matrix interaction, 
migration, cell adhesion and epithelial morphogenesis. 
The same kind of analysis was performed on the 305 genes differentially induced 
between Myc WT and VD. The GO categories scored belong to biological 
functions such as extracellular region, cell adhesion, cell-cell signaling, gland 
development (Table 9). 
	  
GO ID Term p-value 
GO:0044421 extracellular region part 4.87E-11 
GO:0007155 cell adhesion 1.48E-10 
GO:0005509 calcium ion binding 1.10E-06 
GO:0001871 pattern binding 5.17E-04 
GO:0007267 cell-cell signaling 6.86E-04 
GO:0004175 endopeptidase activity 3.00E-03 
GO:0008083 growth factor activity 4.00E-03 
GO:0006029 proteoglycan metabolic process 1.00E-02 
GO:0043062 extracellular structure organization 1.70E-02 
GO:0048732 gland development 1.90E-02 
 
Table 9: The top ten Gene Ontology categories of differentially induced genes between MYC WT and 
VD. The individuated 305 genes induced by MYC WT and less induced/repressed by MYC VD were submitted 
to Gene Ontology analysis (http://david.abcc.ncifcrf.gov). The top ten scoring GO categories are listed with the 
corresponding p-value. 
 
These categories were enriched in the genes differentially induced between MYC 
WT and VD, less in genes commonly induced by the two proteins among which we 
scored gene regulating the interaction with the extracellular matrix and the 
metallopeptidase activity, together with genes belonging to the classical Myc 
induced classes, such as cell cycle, DNA metabolic processes, spindle regulation 
and purine nucleoside binding (Table 10). 
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GO ID Term p-value 
GO:0000278 mitotic cell cycle 1.82E-14 
GO:0005819 spindle 3.53E-05 
GO:0001883 purine nucleoside binding 6.04E-05 
GO:0006259 DNA metabolic process 1.78E-04 
GO:0043169 cation binding 9.10E-04 
GO:0016208 AMP binding 9.98E-04 
GO:0007017 microtubule-based process 1.60E-03 
GO:0031012 extracellular matrix 1.80E-03 
GO:0007268 synaptic transmission 3.50E-03 
GO:0008237 metallopeptidase activity 4.00E-03 
 
Table 10: The top ten Gene Ontology categories of positively regulated genes by both MYC WT and 
VD. The individuated 504 genes induced both by MYC WT and MYC VD were submitted to Gene Ontology 
analysis (http://david.abcc.ncifcrf.gov). The top ten scoring GO categories are listed with the corresponding p-
value.  
 
This could be due to the fact that the Miz1 binding to Myc can regulate, more likely 
indirectly, also the activation of specific classes of genes, in particular those 
regulating cell adhesion, interaction with the extracellular matrix and gland 
development. Myc overexpression, and above all the repressive activity of 
Myc/Miz1, may determine a new cellular organization; in these conditions, some 
targets could be induced simply because of the new phenotype. 
Considering previous observations that verify the influence of Myc/Miz1 complex 
only in the repressive part of Myc transcriptional program (Walz et al., 2014), we 
surmise that the differences observed in the transcriptional activation by MYC WT 
and VD were indirect. In the end, we hypothesize that the mechanism by which 
MYC WT can induce the increment of self-renewal in epithelial cells could be 
mostly mediated by the repression of some of these genes. Thus, the MYC VD 
reduced self-renewal ability observed could be due to the dampening of this 
transcriptional repression. 
3.6.2 microRNA-seq analysis 
Myc modulates gene expression not only through regulation of transcription but 
also post-transcriptionally (Kress et al., 2015). In particular, Myc regulates the 
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expression of several microRNAs (miRNAs) and in this way indirectly controls the 
stability and translational efficiency of their target mRNAs (Bui & Mendell, 2010). 
Either activating or repressing the expression of specific miRNAs, Myc coordinates 
numerous functions pivotal in tumorigenesis and in stem cells differentiation/self-
renewal (Chang et al., 2007; Frenzel, Loven, & Henriksson, 2010; C.-H. Lin et al., 
2009). Given the importance of the miRNAs in breast cancer development (Dvinge 
et al., 2013), we decided to evaluate the effects of MYC (WT or VD) 
overexpression on miRNAs regulation in mammospheres. MYC WT and VD 
overexpressing mammospheres, together with control, were subjected to small 
RNA profiling by miRNA-seq. For each condition three independent samples were 
sequenced obtaining around 1 million reads aligned (see Material and Methods). 
The different species were divided in: canonical miRNA, 3’-modified (nucleotides 
added to the 3' end of the reference miRNA), trimmed (the 5' or 3’ dicing site is 
upstream or downstream from the reference miRNA) and 5’-modified (nucleotides 
added to the 5' end of the reference miRNA) (Nicassio, 2014). The results are 
listed in Table 11. 
	  
 
Table 11: List of counted miRNAs in Ctr, MYC WT and MYC VD primary mammospheres. After filtering 
for expression, miRNAs were subdivided in categories of IsomiRs: canonical miRNA, 3’-modified, trimmed or 
5’-modified. The reads of each category were counted for all the three replicates of each experimental group 
(Ctr, MYC WT and MYC VD overexpressing mammospheres). The total number of miRNAs mapped for each 
category is indicated in the last row. 
 
 Reads 
IsomiR Canonical  3’-modified Trimmed 5’-modified 
Ctr (1) 515767 271050 276926 5104 
Ctr (2) 511400 269882 28064 5621 
Ctr (3) 506783 278376 278246 5800 
Myc WT (1) 498877 418136 186305 7406 
Myc WT (2) 487606 453814 172732 7634 
Myc WT (3) 513686 358163 214669 6785 
Myc VD (1) 513645 363591 210553 6463 
Myc VD (2) 531021 338449 209984 6732 
Myc VD (3) 517521 285124 265063 5774 
Tot. N. 197 550 164 44 
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It is noteworthy that in MYC-overexpressing samples (more WT than VD) the 3’-
modified isomiRs reads are more abundant respect to the controls. Since it has 
been demonstrated that 3’ modifications can be a mechanism for altering miRNAs 
stability and function (Li Guo et al., 2011) and miRNAs isoforms abundance can 
be useful to distinguish breast cancer subtypes (Telonis, Loher, Jing, Londin, & 
Rigoutsos, 2015), we will investigate more in depth this difference. Since the 
canonical miRNAs are the most characterized forms, we decided to focus our 
analysis at first on the 197 canonical miRNAs mapped in our samples. We 
identified 65 miRNAs differentially regulated between Myc overexpressing (both 
WT and VD) and control cells with significant statistical difference (p-value ≤ 0.05; 
FDR ≤ 5%) and |Log2 fold change|>0.5 (Figure 40). The MYC overexpressing cells 
respect to the control cells repressed miRNAs regulating myogenic differentiation 
(mir-133, mir-1, mir-206), while induced miRNAs did not enrich for the regulation of 
a specific function. 
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Figure 40: Differentially regulated miRNAs between Ctr and c-MYC (WT and VD) overexpressing 
primary mammospheres. The heatmap shows all the 65 miRNAs differentially regulated in a statistically 
significant manner (q-value ≤ 0.05; FDR ≤ 5%) in both c-MYC WT and c-MYC VD overexpressing cells 
respect to the Control cells. On the bottom the clusterization of the samples is shown. 
 
	  
Instead 57 miRNAs were differentially regulated between MYC WT and MYC VD 
overexpressing cells (Figure 41). 
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Figure 41: Differentially regulated miRNAs between c-MYC WT and c-MYC VD overexpressing primary 
mammospheres. The heatmap shows all the 57 miRNAs differentially regulated in a statistically significant 
manner (q-value ≤ 0.05; FDR ≤ 5%) between c-MYC and c-MYC VD overexpressing cells. On the bottom the 
clusterization of the samples is shown 
 
Also in this case, MYC VD samples are positioned between MYC WT and Ctr 
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The evaluation of the relevance of the differentially regulated miRNAs for the 
observed phenotype is still ongoing along with a detailed scrutiny of the available 
literature. 
 
3.7 Myc/Miz1 repressed genes in mammospheres: functional 
screening setting 
 
We hypothesized that the genes differentially repressed between MYC WT and 
VD overexpressing mammospheres could be part of the mechanism that underlies 
the different self-renewal capacity of the two cell populations. Reasoning that a 
more stem-like phenotype is also a feature of more aggressive and invasive breast 
cancer (Pece et al., 2010), we are thus planning to functionally characterize those 
genes in order to identify critical mediators of MYC tumorigenic activity. In 
particular, along the lines adopted in a published screening in primary cells 
(Sheridan et al., 2015), we decided to perform a drop-in screen in mammospheres 
(Figure 42). In this way we plan to identify those genes whose knockdown is 
facilitating mammospheres self-renewal and expansion, and thus whose 
repression by Myc could be critical in mediating a more tumorigenic and 
aggressive phenotype. 
For the feasibility of the screening in primary cells, in which we observed the 
phenotype, we decided to shorten the list of candidates that we can screen. 
Indeed, we took into account the following considerations: for each sample we can 
infect 2×106 mammospheres cells (considering that from each mouse we obtain 
about 2×105 epithelial cells), the transduction frequency would be of 40% (in order 
to have only one shRNA/cell), 0.85% of cells will give rise to mammospheres, the 
coverage will be 200 fold for each shRNA (200 cells harbouring the same shRNA), 
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we want to use at least 3 validated shRNAs sequences for each genes and do five 
biological replicates, to be sure about the significance of any shRNA enrichment. 
On this basis we decided that we could handle a total of 180 shRNAs, divided in 4 
pools of 45 shRNAs thus 60 genes. 
For these reasons, we decided to restrict our list of potential candidates on the 
basis also of their biological importance, starting from expression data from breast 
cancer patients and published datasets. 
 
Figure 42: Functional screening of candidate genes in mammospheres. Primary MMECs will be 
transduced with lentiviral shRNAs pools, cloned in a ZIP-SFFV vector (Transomic). The cells, grown as 
mammospheres and selected by Puromycin or ZsGreen marker, will be harvested after 24 hours and 14 days, 
from the transduction. shRNAs representation will be evaluated by: gDNA isolation, shRNA recovery and next 
generation sequencing. The shRNAs enriched at 14 days respect to 24 hours, whose knockdown gives a 
selective advantage to the mammosphere growth, will be the candidate targets by which Myc can induce self-
renewal (modified from Sheridan et al., 2015 and J. Wolf et al., 2013b) 
3.7.1 Breast cancers (TCGA) 
Starting from the idea that the stem cells presence is pivotal in tumorigenesis 
(Stingl & Caldas, 2007), we speculate that the MYC repression of some targets, 
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and the resulting increase in self-renewal ability, can be one of the oncogenic 
mechanisms operated by MYC in breast tumors. Hence, looking for genes that 
could have a role in MYC-driven breast cancer, we analysed the expression of the 
individuated Myc/Miz1 repressed genes in a panel of breast cancers. First, data 
from 1070 human tumors present in The Cancer Genome Atlas (TCGA) database 
were obtained and classified in subcategories (Luminal A, Lumina B, Luminal 
unknown, Triple Negative Breast Cancer or TNBC, HER2+) on the basis of the 
available information about estrogen receptor (ER), progesterone receptor (PR), 
epidermal growth factor receptor 2 (HER2) and Ki67 expression (Voduc et al., 
2010). The expression data were defined as Log2 fold change respect to the 
median of 112 normal breast tissue samples, a t-test analysis was used to define 
genes regulated in statistically significant way in tumors respect to the normal 
counterpart (p-value ≤ 0.05; FDR ≤ 5%). Out of 888 genes of our signature of 
interest, we could univocally assign a human counterpart to 754 that were used for 
further analysis. 23% (177/754 genes) of the genes belonging to the Myc/Miz1 
repressed signature were repressed also in all the human breast cancer samples 
analysed relative to the normal counterpart; while up to 35% (265/754 genes) were 
repressed specifically in the most aggressive Triple Negative Breast Cancer 
(Figure 43). Moreover, we consider the amplification status of the MYC locus in 
these tumors. If we also consider this information and we select just the tumors 
harbouring MYC amplification: 12% (91/754) of the genes belonging to the 
Myc/Miz1 repressed signature was repressed in all the human breast cancer 
samples bearing MYC amplification, while 22% (165/754) were repressed 
specifically in Triple Negative Breast Cancer with amplified MYC. 
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Figure 43: Expression data of Myc/Miz1 repressed signature in a panel of human breast cancer 
(TCGA). Expression of Myc/Miz1 repressed genes in a panel of human breast tumors. Transcriptional data 
from TCGA (1070 tumor samples) were divided in subcategories (Luminal A, Luminal B, Luminal unknown, 
Triple Negative Breast Cancer (TNBC), Her2-type) on the basis of available information. The analysis has 
been done for the 754 (out of 888) genes differentially repressed by MYC WT and VD in mouse 
mammospheres for which a human counterpart could be identified. Expression data are calculated as Log2 
fold change respect to the median of Normal breast tissue (112 sample). 
 
3.7.2 Published datasets  
With the intent to further shortening the list of genes belonging to the Myc/Miz1 
repressed signature selecting those genes which could be biologically relevant 
and on which it will be worth pursuing a more functional analysis, we plan to 
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analyse them also in several published transcriptional datasets. The criteria of 
selection will be the following: 
• Datasets of transcriptional analysis of mouse or human epithelial cells 
subpopulations in the mammary gland (Stromal, Mature luminal, Luminal 
progenitors and Mammary Stem Cells), sorted by surface markers 
(Kendrick et al., 2008; Lim et al., 2009; 2010; Sheridan et al., 2015). 
• Dataset of transcriptional analysis of human breast tumors in which are 
compared CSCs (sorted for surface markers: CD44+ and CD24- or for 
sphere-forming ability) resistant to chemotherapy and the other cancer cells 
of the primary bulk invasive cancer (Creighton et al., 2009). 
Only those genes of the Myc/Miz1 repressed signature down regulated in breast 
cancers overexpressing MYC compared the normal counterpart (previous 
paragraph) and coherently regulated in each dataset (down-regulated in MaSCs 
vs. other subpopulations, down-regulated in CSCs vs. other tumors cells) will be 
taken into account for the functional screening. 
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4. Discussion 
 
The MYC oncogene is a signaling hub in cancer (Dang, 2012) and as such an 
ideal candidate for therapy. Several strategies have been developed to target 
MYC, trying to demonstrate the feasibility to inactivate a molecule that was thought 
to be untouchable owing to its many roles in normal cellular processes (Ponzielli, 
Katz, Barsyte-Lovejoy, & Penn, 2005; Soucek et al., 2008; Vita & Henriksson, 
2006). 
MYC is overexpressed in a wide range of human tumors (Dang, 2012). In breast, 
in particular, MYC is frequently deregulated in cancer cells and preferentially 
detected in the most aggressive tumors (Chen & Olopade, 2008; Xu, Chen, & 
Olopade, 2010). We thus decided to set up a system to profile the specific 
transcriptional response governed by Myc in mammary epithelial cells, in order to 
find new downstream targets, through which it may regulate pivotal functions in 
tumor initiation and maintenance such as adhesion, migration and self-renewal. 
 
4.1 Myc negatively controls the expression of genes involved in 
extracellular matrix interaction, cell adhesion and epithelial 
morphogenesis in mammary epithelial cells 
We defined the core of Myc regulated transcriptional program in immortalized 
murine mammary epithelial cells (MMECs) through genome-wide transcriptional 
analysis, upon either deletion or super-activation of Myc. The main biological 
processes promoted by Myc-induced genes are proliferation, biosynthetic 
metabolism, ribosomal biogenesis, RNA processing and apoptosis as also 
described in several other models (Zeller, Jegga, Aronow, O’Donnell, & Dang, 
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2003; Herkert & Eilers, 2010; Kress, Sabò, & Amati, 2015). On the contrary Myc 
negatively regulates genes involved in lysosome and vesicle-mediated transport, 
GTPase regulator activity, extracellular matrix interaction, epithelial development 
and morphogenesis. These signatures endorse the role of Myc in regulating 
functions that shape the morphology of the cells and their interplay with the 
microenvironment (cell adhesion, interaction with extracellular matrix, cytoskeleton 
organization) (Coller et al., 2000; Shiio et al., 2002, Elkon et al., 2015), the effects 
of which are still not completely clear and seem to be highly context-dependent. 
Indeed, in some contexts (e.g. keratinocytes, HSCs), by modulating the interaction 
with the local microenvironment, Myc induces cell differentiation and depletes the 
stem cell reservoir, due to an inadequate retention in the niche (Frye, 2003; 
Gebhardt, 2006; Wilson, 2004). In other cases, the repressive activity of Myc on 
cell adhesion, has been observed to accompany transformation processes 
(Akeson & Bernards, 1990) and contribute to a more aggressive and metastatic 
phenotype (Wolfer & Ramaswamy, 2011), also dramatically changing cell 
morphology by acquisition of mesenchymal features (Bin Cho, Cho, Lee, & Kang, 
2010; Cowling & Cole, 2007; Smith et al., 2008; Trimboli et al., 2008). This topic is 
of particular interest since loss of the typical epithelial features of adhesion, 
morphology and differentiation has been shown to be one crucial step in the 
acquisition of a stem-like status, which correlates with the capacity to act as 
cancer stem cells (Mani et al., 2008; Morel et al., 2008). However, even within the 
same tissue, in this case the mammary epithelium, the evidences regarding the 
effects of Myc on cell adhesion and migration appear to be discordant. Indeed, 
Myc is an activator of cell motility and invasiveness (Wolfer & Ramaswamy, 2011), 
but in some cases it acts as suppressor of these processes (Cappellen, Schlange, 
Bauer, Maurer, & Hynes, 2007; Liu et al., 2012). The divergent role of Myc in 
different epithelial cell lines could be due to its interaction with distinct cofactors 
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(Patel, Loboda, Showe, Showe, & McMahon, 2004) that leads to a differential 
transcriptional regulation, highlighting the importance of the specific cellular 
context. 
Our experiments show that in immortalized mammary epithelial cells Myc 
negatively regulates the expression of genes involved in extracellular matrix 
interaction, cell adhesion and epithelial morphogenesis, leaving open the question 
of whether this may affect in some way the balance between cell differentiation 
and self-renewal. The answer to this question will be particularly relevant in the 
case of aberrant Myc activation in the mammary gland (Liao & Dickson, 2000), 
due to the emerging hypothesis of the cancer stem cells. 
 
4.2 Myc enhances self-renewal in primary mammary epithelial 
cells through interaction with Miz1 
Among the factors cooperating with Myc in its repressive function, Miz1 appears to 
be one of the most relevant (Peukert et al., 1997). Indeed, Miz1 is essential in the 
down-regulation of 25-40% of Myc repressed genes (Walz et al., 2014), and is 
very likely to be involved in co-regulation of adhesion and self-renewal related 
genes (Gebhardt, 2006; Herkert et al., 2010; Kerosuo et al., 2008). With the aim to 
further investigate the mechanisms of transcriptional repression by Myc in 
mammary epithelial cells, and in particular the role of the Myc/Miz1 interaction, we 
took advantage of a Myc mutant (MYC V394D, here MYC VD) impaired in its 
interaction with Miz1 (Herold et al., 2002). In order to address the role of Myc/Miz1 
binding in promoting self-renewal, primary mammary epithelial cells conditionally 
overexpressing MYC WT or VD, have been grown in non-adherent conditions in a 
clonal sphere-forming assay (Dontu et al., 2003). In general, MYC overexpressing 
cells showed increased self-renewal compared to control cells. However, cells with 
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MYC VD up-regulation exhibited a milder effect relative to their MYC WT 
counterpart.  
Since Myc is pivotal in cell cycle regulation (Amati, Alevizopoulos, & Vlach, 1998; 
Oster, Ho, Soucie, & Penn, 2002) and its interaction with Miz1 is essential for the 
induction of apoptosis (Patel & McMahon, 2006), we checked both proliferation 
and cell death in MYC-overexpressing mammospheres, to clarify the role of these 
phenomena in the observed phenotype. In our hands, MYC up-regulation in 
mammary epithelial cells grown as mammospheres induced proliferation but, 
differently from what expected, decreased apoptosis. The latter result could be 
due to the low levels of MYC overexpression, below the threshold required for cell 
death induction (Murphy et al., 2008). Furthermore, since cells in non-adherent 
conditions undergo massive death due to anoikis, a mild MYC overexpression 
could increase the resistance to anoikis. In this context, MYC proliferative and 
apoptotic potential seems to be mainly independent from Miz1, since MYC WT 
and VD up-regulation had very similar effects. 
The difference between MYC WT and VD in supporting self-renewal has been 
further confirmed in vivo by cleared fat pad reconstitution assay, in which stem cell 
frequency (evaluated by mammary outgrowths) was higher in MYC 
overexpressing cells relative to control cells, with MYC VD overexpressing cells 
yielding intermediate values. Our results corroborate previous indications about 
the positive role of MYC in promoting mammary stem cell and progenitor functions 
(Moumen et al., 2012; Pasi et al., 2011) and, at the same time, suggest that Miz1 
is involved in this effect. This is in line with what previously pointed out in 
neurospheres, in which Myc enhances self-renewal via Miz1, (Kerosuo et al., 
2008). 
The fact that the highest differences in sphere-forming ability between MYC-
overexpressing and control cells were observed at the first two passages (M2-M3) 
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could suggest that MYC acts mainly by increasing the proliferation of the 
progenitor population, which has a finite lifespan (Visvader, 2009). While plausible, 
this scenario would not explain the self-renewal long-term phenotype, which 
requires an effect on the stem cells pool either through an expansion of the stem 
cells themselves or through reprogramming of progenitors to a stem-like status. 
Our results do not currently allow distinguishing between these two possibilities, 
both scenarios being compatible with the results obtained in mammospheres and 
in transplantation assays. To discriminate between the two hypothesis, one should 
induce MYC overexpression only in selected sub-populations, identified by surface 
marker staining (Stingl, 2009) or PKH26 dye retention (Cicalese et al., 2009); 
since only stem/early progenitor cells are able to regenerate mammospheres and 
to reconstitute cleared fat pad, MYC overexpression specifically in purified 
progenitor/differentiated cells could be useful to verify the hypothesis of MYC 
reprogramming of these cells. Data obtained in this way in Pier Giuseppe Pelicci’s 
group suggest that Myc up-regulation could expand the stem cell compartment 
both by inducing symmetric division of the stem cells and by reprogramming the 
progenitors cells (personal communication). Repeating this kind of experiments 
with MYC WT and MYC VD would help to dissect the specific contribution of Myc-
mediated transcriptional repression to each of these processes. 
 
4.3 The Myc/Miz1 interaction is necessary for repression of genes 
involved in extracellular matrix interaction, cell adhesion and 
epithelial morphogenesis in primary mammary epithelial cells 
To investigate the transcriptional program that controls self-renewal, we performed 
whole-genome expression analysis in primary non-adherent mammary epithelial 
cells overexpressing MYC WT and VD. Both forms of MYC were able to induce an 
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overlapping set of approximately 600 genes, which was enriched in genes related 
to cell cycle, DNA metabolic processes, spindle regulation or purine nucleoside 
binding. A smaller set of genes (ca. 300) was induced preferentially in MYC WT 
overexpressing mammospheres: since the VD mutation does not affect Myc/Max 
association and transcriptional activation (Walz et al., 2014), defects in gene 
activation by MYC VD were most likely indirect and probably they reflect the 
phenotype of enhanced self-renewal ability in MYC WT overexpressing cells. The 
genes included in this list were related to extracellular region organization, cell 
adhesion, cell-cell signaling and gland development. On the other side, loss of 
Myc/Miz1 interaction mainly affected MYC mediated transcriptional repression, 
with more than 800 genes repressed by MYC WT more effectively than by MYC 
VD. While this effect is most likely a direct consequence of loss of Miz1 binding by 
MYC VD mutation, ChIP experiments mapping MYC WT, MYC VD and Miz1 
biding to the genome, along with Miz1 loss of function experiments, would be 
needed to formally prove which are the direct and indirect transcriptional effects. 
The main gene ontology category describing the genes differentially repressed by 
MYC WT and VD were related to extracellular matrix organization, cell adhesion 
and epithelial morphogenesis. Similar categories are enriched in genes 
(approximately 500 genes) repressed by both forms of MYC. The repression of the 
genes mediating these functions could be crucial in MYC -induced increase in self-
renewal and Myc/Miz1-mediated repression can contribute to this process. 
For a thorough characterization of MYC transcriptional program, we also profiled 
the expression of microRNAs in primary mammary epithelial cells grown as 
mammospheres. Indeed, MYC can modulate gene expression at different levels 
and the microRNAs are an effective system by which it may tune the stability and 
translation of large numbers of transcripts (Bui & Mendell, 2010). Moreover, 
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several of the known MYC-regulated miRNAs control genes involved in 
differentiation and self-renewal (Lin, Jackson, Guo, Linsley, & Eisenman, 2009). 
We first noticed that MYC-overexpressing cells have an increment of the 3’-
modified isomiRs. Since these miRNAs isoforms have been described to be 
endowed with different stability and function respect to the canonical miRNAs (L. 
Guo et al., 2011), and have been proposed as biomarkers to diagnose and classify 
breast tumors (Telonis, Loher, Jing, Londin, & Rigoutsos, 2015), this effect will be 
further investigated along with a detailed scrutiny of the available literature to 
identify among the differently regulated miRNAs possible relevant mediators of the 
observed phenotype. 
 
4.4 Myc/Miz1 repressed genes in mammospheres: new mediators 
of Myc pro-self-renewal activity in mammary epithelial cells 
At present, our working hypothesis is that Myc enhances self-renewal in mammary 
epithelial cells by repressing some of the identified genes. Hence MYC VD, losing 
this repressive activity, would exert a milder effect. To verify the proposed 
mechanism, we will perform an shRNAs screen to identify genes, among those 
repressed by MYC WT, whose knockdown gives a selective advantage to the cells 
grown as mammospheres (drop-in screen). In order to perform this screen in the 
same primary cells in which we observed the phenotype, we are forced to limit the 
list of screened candidates. In particular considering number of epithelial cells 
obtained from each mouse, transduction frequency, percentage of cells giving rise 
to mammospheres, library coverage, number of shRNAs/gene and number of 
biological replicates we decided that is feasible to screen about 50-100 genes. Our 
selection criteria are based on the biological relevance of the genes relative to our 
aim. In particular, we will select: (I) genes repressed in MYC-amplified breast 
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tumors compared to normal tissue (TCGA data, http://cancergenome.nih.gov), (II) 
genes that show low expression in stem cells compared to differentiated epithelial 
cells (Kendrick et al., 2008; Lim et al., 2009; 2010; Sheridan et al., 2015), or (III) in 
cancer stem cells relative to the bulk tumor population (Creighton et al., 2009), (IV) 
genes repressed by Myc/Miz1 in other datasets (Wiese et al., 2015). We also tried 
to compare the regulated genes in mammary epithelial cells in adhesion or grown 
as mammospheres, but we scored a limited overlap that should be due to context-
dependency of Myc transcriptional responses. We are currently setting up the 
experimental conditions for the functional screen, thereby we hope to individuate 
and validate new downstream targets of Myc relevant in mediating its capacity to 
induce self-renewal. Since this ability is closely linked to the tumor aggressiveness 
(Pece et al., 2010), inhibiting Myc repression of these targets or rescuing their 
activity could be useful for reducing the malignancy of MYC-addicted breast 
cancers. 
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Appendix  
This study started with the aim to profile Myc and TGFβ transcriptional programs in 
mammary epithelial cells, to verify if these two pathways can crosstalk and 
eventually cooperate in tumor formation. The initial hypothesis was that Myc could 
be one of the crucial molecular players in the switch from tumor suppressor to 
tumor promoter of TGFβ. Given that idea, we performed genome-wide 
transcriptional analysis in the immortalized mouse mammary epithelial cells 
(MMECs) with Myc loss/gain of function described above also in the presence or in 
the absence of TGFβ treatment, at a time point (two hours) that we had previously 
chosen on the basis of the peak of transcriptional induction of known TGFβ targets 
such as Snail and PAI1 (Figure 44A). However, TGFβ treatment in our cellular 
model produced only modest transcriptional changes, even if it has been 
confirmed by Gene Ontology analysis that the transcriptional activation reflects a 
typical TGFβ response. Indeed the number of differentially expressed genes in 
response to TGFβ was an order of magnitude smaller than that in response to Myc 
modulation (hundreds compared to thousands) (Figure 44B). Moreover, at least in 
this model, almost all the TGFβ transcriptional targets did not show a different 
regulation upon Myc modulation (Figure 44C). Given these results, we decided to 
focus our attention on the transcriptional response to Myc itself and that become 
the main topic of the project as also described above. 
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Figure 44: Analysis of Myc and TGFβ  transcriptional responses in MMECs. (A) Time course of TGFβ 
induction in MMECs, the transcriptional activation of TGFβ pathway is verified by two of its known targets 
(Snail and PAI1). The mRNA level is normalized on Rplp0 housekeeper gene. (B) The number of differentially 
expressed genes in Myc loss (+TAT-Cre) and gain (+OHT) of function samples and in TGFβ-treated samples. 
The genes whose expression is Myc-dependent are about six thousands; in comparison the TGFβ-dependent 
genes are about five-eight hundreds (C) The TGFβ transcriptional responses in the absence or in the 
presence of overexpression of Myc. The significant differentially expressed genes are highlighted: the up-
regulated in red, the down-regulated in green. 
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